iaslc 2015 annual report
DESCRIPTION
This 2015 Annual Report of the IASLC (International Association for the Study of Lung Cancer) report highlights the progress and achievements over the past year and sets the tone for the upcoming year. Thanks to the hard work of our dedicated staff and the worldwide support of our members, 2015 was a banner year for the IASLC and for progress in lung cancer treatment. Among the major highlights from 2015 are the completion of two of IASLC’s global initiatives: The 8th Edition of the Tumor, Node and Metastasis (TNM) Classification of Lung Cancer, this time including the thymus and esophagus, and the 2015 WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart (Fourth edition). Congratulations to all those involved in these very significant projects. Additionally in 2015, we smoothly transitioned our journal, Journal of Thoracic Oncology, to a new publisher, Elsevier. The first issue published by Elsevier debuted in January 2016.TRANSCRIPT
IASLCI N T E R N A T I O N A L A S S O C I A T I O N F O R T H E S T U D Y O F L U N G C A N C E R
2015 Annual Report
Alex A. Adjei, MD, PhD, FACP, Editor-in-ChiefVolume 11, Number 2, February 2016
Journal ofThoracic Oncology
Of cial Publication of the International Association for the Study of Lung Cancer www.jto.org
JTHO_v11_i2_COVER.indd 1 24-12-2015 16:35:07
WELCOME TO THE IASLC
16TH WORLD CONFERENCE
ON LUNG CANCER
Conference Program Book
FOLLOW US ON TWITTER @IASLC #WCLC2015
FOLLOW US ON FACEBOOK
WWW.IASLC.ORG
BECOME A MEMBER OF IASLC VISIT WWW.IASLC.ORG
3ANNUAL REPORT 2015
Table of Contents
Introduction 4
OrganizationStructure 5
Membership 10
Communications 12
Fellowships 14
EducationalActivities 16
Publications 19
Meetings 26
Awards 34
SponsorsandAdvocacyPartners 38
StrategicPlan 39
IASLCFoundation 44
FuturePerspective 46
IASLCinPublications 47
4IASLC
Thanks to the hard work of our dedicated staff and the worldwide support of our members, 2015 was a banner year for the IASLC and for progress in lung cancer treatment.
Lung cancer remains a major global health problem. Worldwide, more than 1.8 million individuals are diagnosed with the disease, which causes 1.6 million deaths, every year. However, as we saw in 2015, major scientific advancements offer new hope to many lung cancer patients.
While the survival rate for many with lung cancer remains low, new targeted therapies and immunotherapies have the ability to change those statistics. Just this year, two immunotherapy drugs were approved by the U.S. FDA for lung cancer therapy. Immunotherapy continues to demonstrate very encouraging results, particularly in patients who have failed first-line therapy. Lung cancer screening with low-dose computed tomography (CT) has been demonstrated to reduce the lung cancer mortality by 20 percent in high-risk individuals. New advancements in molecular biology provide knowledge of heterogeneity of lung cancer, leading to personalized therapy. As we identify more subgroups it will have a dramatic effect of creating even more specific targeted therapies. All this has transformed lung cancer research and treatment into a role model for modern cancer treatments.
Among the major highlights from 2015 are the completion of two of IASLC’s global initiatives: The 8th Edition of the Tumor, Node and Metastasis (TNM) Classification of Lung Cancer, this time including the thymus and esophagus, and the 2015 WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart (Fourth edition). Congratulations to all those involved in these very significant projects.
In 2015, we smoothly transitioned our journal, Journal of Thoracic Oncology, to a new publisher, Elsevier. The first issue published by Elsevier debuted in January 2016.
Never in our history has the IASLC enjoyed the outreach we had in 2015; our accomplishments vaulted our membership to a record high of more than 5,000 members in more than 100 countries. In addition to our successful webinars in both the U.S. and Europe, the IASLC School of Thoracic Oncology arranged several Live Learning programs, designed for fellows and junior faculty members in particular.
We enjoyed incredible success in all our 2015 meetings, notably the World Conference on Lung Cancer (WCLC) in Denver which gathered over 6,000 participants from nearly 100 countries and showcased many new advances in lung cancer science. We also launched more focused, smaller meetings, such as the Small Cell Lung Cancer meeting
and the consensus meeting on Management of EGFR Mutant NSCLC.
The new IASLC Mentorship Award provided experienced IASLC mentors to 13 fellows during the WCLC. After the conference, they spent one week at a U.S.-based academic institution.
Because of the rapid pace of the progress in lung cancer, our molecular guidelines committee is already working to revise the IASLC/CAP/AMP Guidelines for Molecular Testing in NSCLC, new revisions of the ALK Atlas, which will now include ROS1, and development of a PD-L1 Atlas, which should help physicians and patients select the most appropriate immunotherapy treatment. While immunotherapy emerged as a promising treatment for lung cancer, the predictive assays related to this raised issues which the IASLC, together with other organizations, took the lead to solve through a coordinated Blueprint Project in collaboration with industry partners.
A core value for the IASLC is to develop and educate the next generation of investigators. Our generous members and outside donors gave strong support to the IASLC Foundation in 2015 and we look forward to expanding the Foundation and its support for young investigators to continue preventive and therapeutic scientific developments worldwide in the years to come.
We already have our sights set high for 2016. We will expand on our 2015 accomplishments with an additional emphasis in Asia and we will launch a new magazine that will include commentaries on all aspects of lung cancer science and management. The IASLC is also expanding our staff and office space to meet the growing demand for our support.
At the conclusion of this successful year, we thank our members and our staff for their commitment to the IASLC and to our mission to reduce lung cancer mortality all over the world.
Introduction
Fred R. Hirsch, MD, PhD David P. Carbone, MD, PhD ChiefExecutiveOfficer President
5ANNUAL REPORT 2015
Organiza�on
President
USA2015-2017
President Elect
Italy2015-2017
Past President Tony MokHong Kong2015-2017
Past President
United Kingdom2013-2015
Chief
USA
Treasurer
USA
Alex AdjeiUSA
2011-2015USA
2011-2015Germany
2011-2015
Tetsuya MitsudomiJapan
2011-2015Japan
2011-2015
Silvia NovelloItaly
2011-2015
Thailand2011-2015
USA2013-2017
USA2013-2017
United Kingdom2013-2017
iFrance
2013-2017Japan
2013-2017
Switzerland2013-2017
China2013-2017
Australia
2015-2019
USA
2015-2019Japan
2015-2019Austria
2015-2019
Germany2015-2019
Japan
2015-2019USA
2015-2019USA
2015-2019
2013-2017
6IASLC
Position NameChiefExecutiveOfficer FredR.Hirsch
DirectorofEducation,CorporateRelationsandGovernance PiaHirsch
DirectorofFinance JohnSkadow
DirectorofMembership KristinRicheimer
DirectorofCommunications JeffWolf
ScientificProjectsManager MurryWynes
CMEEducationCoordinator PaulSilvey
JTO Managing Editor MaryTodd
ProjectsSpecialist BeckyBunn
DataandTechnicalAnalyst MichelleGarcia
ScientificProjectsSpecialist JacintaWiens
AsianOffice VengieLau
IASLC Committees (2015-2016)
IASLC Staff
Committee Chair Past-Chair 2015 AccomplishmentsAwards DavidCarbone TonyMok Selectedthe2015IASLCDistinguishedAwardwinners.
Bylaws ToBeAnnounced
CareerDevelopmentandFellowship
BenSolomon MartinEdelman/BenjaminBesse
TheCommitteereviewedandrankedseveralFellowshipapplications during2015,evaluatingyoungresearchersinordertorewardscientificexcellenceandtoencourageinnovativeresearchinlungcancerpreventionandtranslationalmedicineworldwide.InthecomingyearmoreawardswillbereviewedandselectedandtheCommitteewilldevelopCareerDevelopmentinitiativesforIASLC.
Communications RossSoo AnneTsao TheCommunicationsCommitteeplayedakeyroleinleadingcommunicationseffortsforthe16thWorldConferenceonLungCancerinDenver,helpedguidepromotionaleffortsforarticlesintheJournal of Thoracic Oncology(JTO),improvedthedeliveryofIASLC’smonthlynewsletterandprovidededitorialassistanceforthedailynewspaperattheWCLC.
Education FedericoCappuzzo SureshRamalingam TheCommitteedevelopedmultidisciplinarycurriculumforfellowsandyounginvestigatorswhichispostedontheIASLCwebsite.TheCommitteealsoevaluatedrequestsforIASLCendorsedmeetingsanddevelopedLiveLearningProgramswhichwereinitiatedin2015andwillcontinueinthefuture.
AdvancedRadiationTherapy(ART)
LaurieGaspar FrancoiseMornex
HakChoy ThisSubcommitteeoftheEducationCommitteecontinuedthegrowthandexpandedtheIASLCwebinarprogram,whichstartedin2012,worldwide.
ContinuingMedicalEducation(CME)
RamaswamyGovindan
ThisSubcommitteeoftheEducationCommitteeensuresadherencetoCMErules,identifyingambassadorstomonitorallIASLCmeetings.
Ethics ThierryMarieJahan EduardoRichardet/ThierryMarieJahan
In2015,theEthicsCommitteeworkedtohelpstreamlinetheConflict OfInterestsubmissionprocessfortheBoard,CommitteeMembersandallIASLCvolunteers.TheCommitteeseekstobeproactiveon emergingissuesandbestpracticesaroundtheworld.
Finance DavidGandara FredR.Hirsch EnsuredthattheIASLCmaderesponsibleandsoundfinancialdecisions.
7ANNUAL REPORT 2015
Membership LuisRaez SurishSenan TheMembershipCommitteeoversawanotherrecordyearofIASLCmembershipin2015.VolunteersfromtheMembershipCommitteeservedasambassadorsattheIASLCExhibitBoothatvariousmeetingsandalsoworkedtointroducenewpartnersocietiestoIASLCforjointmembershipoffers.TheCommitteeexpandedtheIASLCfreeFellowMembershipprogramtoallowgroupregistrationandwillcontinuetoencourageglobalgrowthinallregionsandsub-specialties,particularlythosecurrentlyunder-representedinIASLCMembership,suchasRadiationOncology,Pulmonology,Pathology,andNursingandAlliedHealthProfessions.
Nominating JoanSchiller KathyAlbain Selectedtheslateofpotential2015-2017BoardofDirectorscandidates.
Nurses&AlliedHealthProfessionals
JohnWhite PatriciaHollen TheCommitteepromotedaResourceCenterwhichreceivednearly10percentofallIASLC.orgwebsitetrafficMarch-December2015,developedanagendaforN&AHPsessionscompletedforthe2015WCLCConferenceandwroteamanuscript,“Supportivecareinlungcancer:Milestonesoverthepast40years,”recentlypublishedintheJTO.
Pathology YasushiYatabe AndrewNicholson TogetherwiththeWHO,thePathologyCommitteedevelopedthenewWHOClassificationofTumoursoftheLung,Pleura,ThymusandHeart.
PatientAdvocacy GlendaColburn GlendaColburn TheCommitteelaunchedseveralnewinitiatives,mostlyfocusedonWCLCin2015,includingaPatientAdvocacyTrackatWCLC,uniqueregistrationratesforadvocates,survivorsandadvocacyorganizations,creatingpatientlocalliaisonsandadvocacytravelgrants.
Prevention,Screening&Early
Detection
ToBeAnnounced NirPeled TheCommitteeheldanall-daysoldoutworkshoponplanningfortheimplementationoflungcancerCTscreeninginternationallyatWCLC2015andhadacomprehensiveprevention,screening,andearlydetectionprogrambecauseoftheworkbythecommitteeanditsmembers.Committeememberswroteadocumentonestablishingalungcancerscreeningclinic,withtheaimofhelpingcentersthroughastandardizedapproach.TheCommitteeisalsoworkingondocumentsandtoolsonthewebsiteforriskassessment,nodulemanagement,andinformationonwhatdatashouldbecollected.Movingforward,theCommitteewilladdressgroundglassopacitymanagementandthecreationofanimageatlasinordertostandardizeandsupportbetterclinicaldecisions.
Publications DavidSpigel HarveyPass ThePublicationsCommitteeassistedinthedecisiontomovetoanewpublisherfortheJournalofThoracicOncology,takingpartinthedecisiontomovethejournaltoElsevier;openeddiscussionswithElsevieraboutaneweditionoftheIASLCtextbook;helpedtodeveloparticlesdetailingtheprogressinlungcancerin2015fortheJTO; andlooksforwardtohelpingwiththelaunchofthe newmagazine,IASLCLungCancerNews,in2016.
Staging RamonRami-Porta PeterGoldstraw TheStagingCommitteedevelopedthe8thEditionoftheStagingofLungCancer.SeveralpublicationshavealreadybeenpublishedintheJTO.
TobaccoControl/SmokingCessation
MichaelCummings CarolynDresler TheCommitteeproducedamonthlyJTOsectiononglobaltobaccocontrolandsmokingcessation.TheWCLC2015hadthemostcomprehensivetobaccocontrolandsmokingcessationprogramforanyworldconference,includingthelaunchofaCommittee-updatedIASLCStatementonTobaccoControlandSmokingCessation.TheIASLC,attherecommendationoftheCommitteeandinassociationwithdozensofothersocieties,signedontomultiplepolicylettersrelatedtotobaccocontrolin2015.EducationalTobaccoExhibitsproducedbytheMedicalUniversityofSouthCarolinaandtheRoswellParkCancerInstituteweredisplayedatmultipleIASLCmeetings.TheCommitteesponsoredtwowebinarsin2015.AbrochureonsmokingcessationandtobaccocontrolforphysicianswasstartedbytheCommitteeandwillbelaunchedin2016.
AsiaPacific LungCancer
SumitraThongprasert
PlannedtheAPLCCmeetingsinSoutheastAsia.
8IASLC
Task Force Chair(s) Past ChairIndustry GiorgioScagliotti
PaulA.Bunn,Jr.RolfStahel
QualityandValue RonanKelly
Regent Area Regent Name Specialty & LocationAustralasia NickPavlakis MedicalOncology,SydneyBrasil MauroZamboni ThoracicSurgery,RiodeJaneiroCanada GailDarling(Chair2012-2015) ThoracicSurgery,TorontoCentralAmericaandMexico OscarArrieta MedicalOncology,MexicoCityCentralEurope GyulaOstoros MedicalOncology,BudapestChina Yi-LongWu ThoracicSurgery,GuangzhouEurope(1) RudolphHuber MedicalOncology,MunichEurope(2) LucioCrino MedicalOncology,PerugiaEurope(3) PauldeLeyn ThoracicSurgery,LeuvenEurope(4) CecilelePechoux RadiationOncology,ParisGreece IoannisGkiozos Pulmonology,AthensGulfStatesandArabia KhaledAl-Kattan ThoracicSurgery,RiyadhIndianSub-Continent DigembarBehera Pulmonology,ChandigarhJapan(1) ShujiSakai ThoracicSurgery,TokyoJapan(2) IchiroYoshino ThoracicSurgery,ChibaKorea YoungTaeKim ThoracicSurgery,SeoulNorthAmerica HeatherWakelee MedicalOncology,StanfordNorthAmerica CharlesPowell Pulmonology,Mt.SinaiNorthAmerica BrianLally RadiationOncology,MiamiNorthAmerica GerardA.Silvestri Pulmonology,CharlestonRussia ValeriyBreder MedicalOncology,MoscowSouth-EastAsia IbrahimWahid RadiationOncology,KualaLumpurSouthernAfrica TonyLinegar ThoracicSurgery,CapeTownSpanishSouthAmerica EduardoRichardet MedicalOncology,CordobaTaiwan JamesChih-HsinYang MedicalOncology,TaiwanTurkey DenizYalman RadiationOncology,IzmirUKandIreland RichardBooton Pulmonology,Manchester
IASLC Council of Regents
IASLC Task Forces
9ANNUAL REPORT 2015
Organization OverviewMembers–ThosebelongingtotheIASLCcomefromawiderangeoffieldsandbackgrounds.Ourorganizationbringstogetherclinicalpractitioners,scientists,patientadvocates,nursesandindustryexecutivesunitedinthegoalofprevention,screening,imaging,diagnosisandtreatmentofthoracicmalignancies.Werelyontheexpertiseofourmembersasweworktofindnewwaystocollaborateandsharethemosttimelyandrelevantscientificandclinicalinformationaroundtheworld.LeveragingtheseresourcespositionstheIASLCasthepremierglobalsourceofinformationonthoracicmalignancies.MembersdevotetheirtimetoleadingIASLCsponsoredmeetingsandconferences,takeactiverolesinvariouscommittees,providepresentationsoncutting-edgebasic,translational,andclinicalscienceandengageinrobustinteractionstofurthertheIASLCmission.
Board of Directors–TheIASLCBoardofDirectorsismultidisciplinaryandeachmemberbringsanabundanceofclinicalandscientificexpertise,alongwithabroadbaseofexperiencewithothersocietiesandfamiliaritywithinstitutionalleadership.IASLCboardmemberspromoteongoinggrowthinprogramsandnewinitiativesthroughtheirstrategicguidanceaswellastheiroperationalandfinancialoversight.
Headquarters Staff–UndertheleadershipoftheCEO,thestaffimplementsawiderangeofeducation,membership,communication,outreach,fundraisingandscientificprogramsfortheorganization.Fromfacilitatingmanyworldwideconferencestoproducingwebinars,publishingbooksanddigitalapplications,collaboratingwithcommitteesandmembers,disseminatingthelatestscientificadvancesandworkingwiththemediaglobally,thestaffdistributesthebestandlatestinformationtoourmembersandthepublicacrosstheglobe.Thestaffworksdiligentlytokeepcontactinformationup-to-dateandisaccountableforthemanagementofIASLCfinances,includingobtainingsponsorshipsforvariousactivitiesandevents.Thestaffsupports,givesexpertadviceandhelpsimplementdecisionsmadebyIASLCcommitteesandtheBoard ofDirectors.
10IASLC
IASLC Membership Reaches Record High of 5,000 Members IASLCstaffsetandattainedalandmarkgoalof5,000activemembersin2015,anincreaseof47percentcomparedwith2014,byactivelyengagingwithcurrentmembers,creatingnewandinnovativewaysofreachingnewpotentialmembers,andenrollingarecordofmorethan1,500newmembersthisyear.
Severalkeyinitiativesshouldbecreditedforthisgrowth:
» IASLC Membership Booth Promotions and Partner Society Offers: Launchedasapilotprogramin2015,new membersfromtheseinitiativesamounttoanestimated 10percentoftotalmembers.WithIASLC’sMembershipBoothpresenceatsocietiesforThoracicSurgery,
PulmonologyandMedicalOncologyinEuropeandNorthAmerica,wecontinuetoincreaseIASLCexposureinunder-representedspecialtiesandregionsoftheworld.
» WCLC 2015 Registration:WhilemembershiphistoricallyincreasesduringWCLCyears,IASLCimprovedthedatasharingandregistrationprocessthisyeartocapturemembershipasindividualscompletedWCLCregistration.Inaddition,manynewmemberstookadvantageofthemulti-yeardiscountofferattheWCLCinDenver,Colorado.
» Retention & Recovery:IASLCretainedandrecovered88percentofformermembersandlapsedmembers,whichisanincreaseoverpastyears’retentionrate.
» Early-Career Members: IncreasedpromotionofthefreeFellowmembership,availabletoFellows,ResidentsandTraineesinalldisciplinesledtogrowthinthismembercategory.Weencourageallmembersto“Invite-a-Fellow”orutilizetheGroupFellowRegistrationtomakesureearlycareerphysiciansandinvestigatorscanbenefitfromthisincrediblevalue.
» Improved Technology: Improvementstothememberdatabaseandemailmarketingsoftwareprovidedbettermemberdataandallowedmorefrequentnoticestobedistributedtolapsedmembers.
Membership
2015 Members by Specialty 2015 Members by Region
Cancer Research/ Basic Sciences, 6%
Radiation Oncology/ Diagnostic Radiology,
9%
Pathology, 5% Nursing, 4%
Other, 11%
PulmonaryMedicine,
14%
Medical Oncology,32% Europe,
23%
North America, 35%
Asia, 28%
Rest of the World, 6%
Latin America, 6%
ThoracicSurgery,
20%
11ANNUAL REPORT 2015
Attracting Members from the Entire Multidisciplinary TeamIASLCestablishedagoalofeducatingtheentireteamofprovidersforlungcancerpatients.Tofurtherthatgoal,IASLCupdateditsmembercommunicationstoincludelanguagetomakeitclearthatIASLCmembershipisvaluabletoanyonewhoisinvolvedinlungcanceraroundtheworld.IASLCactivelyseekstoincreaseitsmembershipamong:
• Pathologists• Diagnosticradiologists• Nursesandalliedhealthprofessionals• Communitypractitioners• Industryprofessionals
TheseriesofAdvancedRadiationTechnology(ART)Webinarsprovidedauniquevehicletoattractnewmembersinradiationoncology,andourpartnershipswithsubspecialtysocietiesaroundtheworldincreasethevisibilityandmembershipofIASLC.
Member Engagement and BenefitsIn2015,theIASLCintroducedthemembershipcardandsentonetoallactivemembers.ManymembersbroughttheircardstothemembershipboothtogetanIASLCmemberpinandinvitedcolleaguestojoin.Inaddition,werevivedtheprintedMemberDirectoryin2015andallmemberscouldchoosetoreceiveoneinthemail.Forthefirsttime,welaunchedtheIASLCVirtualLibrarywitheducationalcontentfromWCLC2015and2013,makingitavailabletomembersontheIASLCwebsitethroughtheirIASLCmembershiplogin.MemberswhodidnotattendtheWCLCcouldalsopurchaseaccesstotheWCLC2015VirtualMeetingfor$99USD.Additionally,allactivememberscanaccesstheWCLC2013contentfreeofcharge.Membersandmeetingattendeeswerealsoeagertopickupthe8thEditionTNMStagingCardProposalsatmanymeetingsaroundtheworld.
The Years Ahead - Collaboration Welcome!TheIASLCencouragesmembers,partnersocietiesandindustrypartnerstopursuebeneficialcollaborations.Ahighpriorityforearly2016istheofficiallaunchoftheCorporateMembershipProgram.TheIASLCMembershipDepartmentandMembershipCommitteeremaincommittedtocontinuedaggressivegrowth,particularlyinunder-representedspecialtiesandregionsoftheworld.Wewelcomemembersuggestionsandideasforcollaborations,whichcanbesubmittedanytimetotheIASLCMembershipCommittee,MembershipDirectorortheIASLCRegentinyourlocation.Wethankyouforyourcommitmenttoconqueringthoraciccancersworldwide!
New members from the following societies can receive additional discounts!
12IASLC
In2015,theIASLC’scommunicationseffortsachievedgreaterreachthaneverbefore,garneringmediaattentionandheadlinestoriesaroundtheworld.Duringtheyear,wepublishedmorethan60newsreleases,focusingonscientificadvancements,lungcancerawarenessandthe2015WCLCtopabstractsandawards.OurmediaeffortsincludedasignedlettertotheFDAcommissioneraddressingourcommunity’sconcernswithregulatoryactionthatpreventsresearchonvitalelectronicnicotinedeliverysystems(ENDS),andasignedlettertotheAmericanRedCrossaskingtheorganizationtostopacceptingmoneyfromthetobaccoindustry.IASLChasgreatplansforthefutureofourcommunications,includingbetterandmoretargetedcampaignsandwaystoensureourmembersstayup-to-dateonthelatestinourindustry.
WCLC 2015Duringthe16thWorldConferenceonLungCancerinDenver,IASLCpartneredwithapublicrelationsfirmtoexpandourreachexponentially.OurWCLC2015effortsincludedmorethantwodozenpressreleases,hundredsofemailstomediaprofessionals,fourpressconferences–oneforeachdayoftheWCLC,andmultipleinterviewswithnewsorganizations.
Theseeffortsresultedinmorethan1billionimpressionsandmorethan$400,000inAdValue,including
on-siteinterviewswithmultipleTVstationsandanarticleonthefrontpageofamajornewspaper.
Communications
Figures at-a-Glance
13ANNUAL REPORT 2015
Lung Cancer Awareness MonthNovemberisrecognizedasLungCancerAwarenessMonthinmanycountries,andtheIASLConceagainparticipatedbyhostingevents,sharingsuccessesinlungcancertreatmentwiththemediaandcollaboratingwithinternationalmemberstoraiseawarenessoflungcancer.ThehighlightofoureffortsincludedaLungCancerAwarenessForumattheIASLCheadquarterswhereseverallungcancerpatientsjoinedwithlocaldoctorsandhealthprofessionalstosharetheirstoriesandtocollaboratebysharinginformation.Itwasanemotionalandrewardingexperienceforallandthestaffplanstoholdsimilareventsinthefuture.Additionally,weparticipatedinLungCancerSocialMedia’sTwitterchat,featuringanswersbyIASLCCEODr.FredR.Hirsch.WealsoannouncedthelaunchofanewinitiativebyIASLCtoimprovecommunicationsbetweenpatientsandhealthprofessionals.Lookformoreinformationonthisinitiativeinthecomingyear.OurmessagingthisNovemberfocusedonspreadingregionalfactsaboutlungcancerandondispellinglungcancermyths.TheIASLCalsosucceededingettingmediaoutletstodoseveralstoriestohelpraiselungcancerawarenessandheardfrommanyIASLCmembersfromacrosstheglobeaboutlocaleventstheyparticipatedintoraiseawareness.
NewsletterKeytokeepinginclosetouchwithourmembersisthedistributionofanewsletter,deliveredbyemailtoallmemberseachmonth.ThenewsletterincludesupdatesfromtheIASLCCEOandthePresident,
aswellasinformationonallupcomingevents,newinitiativesandabstractdeadlines.Fellowshipawards,keyJTOarticlesandadvocacyeffortscanalsobefoundfeaturedinthenewsletter.Toreportindetailonglobalactivities,theIASLCRegentsalsoofferinformationaboutinitiativesintheirregions.
Social MediaAsmoreandmoremembersandjournalistsexpandtheiruseofsocialmedia,theIASLCsharpensouruseoftechnologytoprovidequick,streamlinedinformation.IASLC’ssocialmedianumbersconsistentlyroseduring2015withtheIASLCFacebookpageseeingagrowthfromlessthan1,500likesandendingtheyearwithmorethan1,900.TheJTOFacebookpagealsoenjoyedyear-to-yeargrowth,startingwithmorethan2,300likesandendingwithmorethan2,500.TheIASLCTwitteraccountgainednearly700newfollowersduringtheyearandreachedahighpointduringSeptemberwith134,000Tweetimpressionsandnearly5,000profilevisits.
2015 Social Media Growth
3,000
2,000
1,000
0Twitter IASLC JTO
Facebook Facebook
DecemberJanuary
January December
14IASLC
Fellowship/Young Investigator Awards 2015 – 2016 FellowshipsremainakeypartoftheIASLCmission.In2015,IASLCcontinueditssupportforyoungresearchersinordertorewardscientificexcellenceandtoencourageinnovativeresearchinlungcancerpreventionaswellasinclinicalandtranslationalmedicineworldwide.TheIASLCacceptedapplicationsforFellowshipandYoungInvestigatorAwardsinJanuary,withcandidatesrepresentingNorthAmerica,AsiaandEuropeawardedresearchfundingaftercompetingwithaglobalpoolofapplicants.Globalsubmissionstoourfellowshipawardsincludedmanyexcellentcandidates,evaluatedbyaScientificReviewPanelfortheirmerit,innovationandpotentialimpactonthefuturemanagementandtreatmentoflungcancer.In2015,ajointcollaborationbetweenBoehringerIngelheimChinaandIASLCenabledafellowfromShanghai,ChinatocometotheUnitedStatestoperforma1-yearresearchproject.
Mark M. Awad Dana-FarberCancer
Institute,USA
Mentor & Institution: YoungInvestigatorDana-FarberCancerInstitute,USA
Project: DevelopmentofAssaystoDetectAntibodyandT-cellImmuneResponsestoAnaplasticLymphomaKinnsae(ALK)inNon-SmallCellLungCancer(NSCLC)Patients
Puey Ling ChiaTheAustinHospital,
Australia
Mentor & Institution: ThomasJohnTheAustinHospital,Australia
Project: Characterizationofthetumourmicroenvironmentinmesotheliomaforimmunoligicalandoncogenictargetedtherapies
Yayi He (BoehringerIngelheimChineseFellowship&IASLCFellow)
TongjiUniversity, Shanghai,China
Mentor & Institution: FredR.HirschUniversityofColorado,USA
Project: Studyonacquiredresistantmechanismstoafatinib(BIBW2992)inlungadenocarcinomawithHER2mutations
Jill E. LarsenQIMRBerghoferMedical
ResearchInstitute,Australia
Mentor & Institution: YoungInvestigatorQIMRBerghoferMedicalResearchInstitute,Australia
Project: Characterizationsof“cooperative”mutationsfortheirpotentialasacquiredvulnerabilitiesinKRAS-drivennon-smallcellcarcinoma
Colin LindsayInstitutGustave-Roussy,
France
Mentor & Institution: BenjaminBesseInstitutGustave-Roussy,France
Project: AssessingtheclinicalsignificanceofEPCAM-negativecirculatingtumourcellsinnon-smallcelllungcancer
Yoichiro MitsuishiDana-FarberCancer
Institute,USA
Mentor & Institution: MatthewMyersonDana-FarberCancerInstitute,USA
Project: ChemicalscreenforagentsthatdegradethelungcanceroncoproteinNrf2
15ANNUAL REPORT 2015
Sara PilottoUniversityofVerona,Italy
Mentor & Institution: EmilioBriaUniversityofVerona,Italy
Project: Immunecheckpointregulatorsanddrivinggenemutationsasoutcomepredictorsforresectedsquamouscelllungcancer
Adrian G. SacherDana-FarberCancer
Institute,USA
Mentor & Institution: GeoffreyR.OxnardDana-FarberCancerInstitute,USA
Project: QuantitativePlasmaGenotypingasanIntegratedBiomarkerinAdvancedNSCLCTherapy
Kenichi SudaKinkiUniversity,Japan
Mentor & Institution: YoungInvestigatorUniversityofColorado,USA
Project: Foundationalinvestigationtooptimize3rdgenerationEGFR-TKItreatment–analyzingheterogeneityofresistanceandovercomingresistance
Piyada Sitthideatphaiboon(APLCC&IASLCFellow)ChulalongkornUniversity,
Thailand
Mentor & Institution: ViroteSriuranpongandTrairakPisitkun,MDAndersonCancerCenter,USA
Project: ProteomicsignatureforthedifferenceinchemotherapysensitivitybetweenmutantEGFRandwildtypeEGFRinnon-smallcelllungcancer
Silvestre VicentCenterforAppliedMedicalResearch(CIMA),Spain
Mentor & Institution: YoungInvestigatorCenterforAppliedMedicalResearch(CIMA),Spain
Project: DissectingthefunctionalroleofFos-likeantigen1(FOSL1)in KRAS-drivenLungCancer
IASLC would like to thank the following supporters of the IASLC Fellowship/Young Investigators Program:
»AstraZeneca »Boehringer Ingelheim »Bristol-Myers Squibb »Celgene »Daiichi Sankyo »Eli Lilly »Genentech »Pfizer »Prevent Cancer Foundation
16IASLC
Educational ActivitiesTobroadentheavailabilityofeducationalofferings,theIASLCexpandeditsnumberofContinuingMedicalEducation(CME)accreditedprogramsin2015,offering23webinarsondiversetopicsandorganizingmultipleLiveLearningevents.MembersaroundtheworldnowhavetheabilitytolearninpersonatmeetingsandLiveLearningevents,andtolearnfromtheirofficesthroughwebinars.TheIASLCGlobalCurricularFrameworkcontinuestoserveasaresourceforlifelonglearning.
Title: Best of 2014 Lung Cancer Research and High Priority NCI Lung Cancer Trials – CMESpeaker: RoyS.Herbst,MD,PhDModerator: RamaswamyGovindan,MD– ProgramChairDate: January20,2015
Title: Improving therapeutic outcomes for lung cancer patients: addressing the overwhelming evidence about tobacco use and cancer treatment. (Tobacco Control Committee Webinar)Speaker: GrahamWarren,MD,PhDModerator:CarolynDresler,MDDate: January21,2015
Title: Advances in NSCLC: Approaches to the Management of TKI ResistanceSpeakers: JonathanGoldman,MDand HeatheerWakelee,MDDate: February24,2015
Title: Chemotherapy Options for Metastatic Lung Cancer – CMESpeaker: MarkA.Socinski,MDModerator: RamaswamyGovindan,MD– ProgramChairDate: March4,2015
Title: E-Cigarettes: Friend or Foe? (Tobacco Control Committee)Speakers: MaciejGoniewicz,PhD BenToll,MDModerator:MatthewSteliga,MDDate: April1,2015
Title: New Therapies Are Coming for Malignant Pleural Mesothelioma – CMESpeaker: LeeM.Krug,MDModerator:RamaswamyGovindan,MD– ProgramChairDate: April2,2015
Title: Evolving Role of PD-1/PD-L1 Inhibitors in the Clinical Management of NSCLC – CMESpeaker: EdwardGaron,MDModerator:RamaswamyGovindan,MD– ProgramChairDate: June17,2015
Title: Current Role of Immunotherapy for Lung Cancer – CMESpeaker: ScottN.Gettinger,MDDate: June25,2015
Title: Advanced Radiation Technology Committee Live Webinar Series - Making Progress in Stage III NSCLC Management – CMESpeakers: DavidBall,MD MichaelMacManus,MDModerator: FrancoiseMornex,MD–ProgramChairDate: July9,2015
Title: Biomarkers and Personalized Medicine for Patients with Lung Cancer – CMESpeaker: Prof.KeithKerr,MDModerator:RamaswamyGovindan,MD– ProgramChairDate: July14,2015
IASLC Webinar Programs - 2015
17ANNUAL REPORT 2015
Title: Combined Modality Treatment of Stage III NSCLC – CMESpeaker: SureshSenan,MDModerator:RamaswamyGovindan,MD– ProgramChairDate: July20,2015
Title: Advanced Radiation Technology Committee Live Webinar Series: Follow-up of patients after SABR (stereotactic ablative radiotherapy) for early stage NSCLC-A Primer for the Multidisciplinary Team – CMESpeakers: DavidPalma,MD SureshSenan,MDModerator: FrancoiseMornex,MD–ProgramChairDate: July21,2015
Title: EGFR TKIs: What is New? – CMESpeaker: LeciaSequist,MDModerator:RamaswamyGovindan,MD– ProgramChairDate: August26,2015
Title: Surgical Standards for NSCLC – CMESpeaker: WalterWeder,MDDate: September1,2015
Title: Advances in Radiation Therapy for Non-Small Cell Lung Cancer – CMEModerator:FrancoiseMornex,MD,PhDSpeakers: YasushiNagata,MD YongChanAhn,MDDate: September25,2015
Title: Ongoing Clinical Trials for Patients with Advanced Lung Cancer – CMEModerator:RamaswamyGovindan,MDSpeaker: DavidGandara,MDDate: October1,2015
Title: IASLC WHO Pathology Classification 2015 – CMESpeaker: AndrewNicholson,MDDate: October8,2015
Title: ASCO/IASLC 2015 Lung Cancer Updates for Radiation Oncologists – CME Moderator:LaurieGaspar,MDSpeakers: CliffordRobinson,MD SaimaWaqar,MDDate: October12,2015
Title: Staging of Lung Cancer – 2015 – CMESpeaker: RamonRami-Porta,MDDate: October14,2015
Title: WCLC 2015 UPDATE Moderator: RamaswamyGovindan,MDSpeaker: SureshRamalingam,MDDate: October21,2015
Title: Lung Cancer in Women – CMESpeaker: SilviaNovello,MDDate: November10,2015
Title: Challenging Cases in Early Stage Non-Small Cell Lung Cancer – CMEModerator:RamaswamyGovindan,MDSpeaker: HeatherWakelee,MDDate: November18,2015
Title: Challenging Cases in Advanced Stage Non-Small Cell Lung Cancer – CMEModerator: RamaswamyGovindan,MDSpeaker: AnneTsao,MDDate: December8,2015
18IASLC
Live LearningIASLChostedthreeLiveLearningeventsonmultidisciplinarytopics(pulmonology,medicaloncology,surgery,radiationoncologyandpathology)in2015.Theseworkshopswereopentophysiciansandalliedhealthprofessionalsinvolvedinthecareofpatientswithlungcancerandwereparticularlysuitedforearlycareerphysiciansandtrainees.ThesewereheldinNewYork,AtlantaandSanFranciscowithhugesuccess.TheIASLCplanstocontinuethisprojectin2016.
InDecember2014,CHEST,theAmericanSocietyforClinicalPathology,theNationalComprehensiveCancerNetwork®(NCCN®),IASLCandTheFranceFoundationdevelopedalivelearningexperiencecalledGAIN(EnGAgingAnInterdisciplinaryTeam)forNSCLCDiagnosis,PersonalizedAssessmentandTreatment.Throughcase-baseddiscussionsandinteractivesimulations,GAINinterdisciplinarysummitssoughttoaddressspecificunmetneedsandclinicalgapsinthecareofpatientswithlocallyadvancedandmetastaticnon-smallcelllungcancer(NSCLC).Thegoalofthesummitswastoadvancetheknowledge,competence,andperformanceofateamofinterdisciplinaryspecialistswhoarecurrentlyresponsibleforappropriatestaging,mediastinallymphnodeassessment,tissueacquisition,biomarkeranalysisandimmunotherapyinpatientswithNSCLC.Throughout2015, 12GAINeventswereheld:eightintheU.S.andfourinEurope.
Global Curricular FrameworkTheEducationCommitteedevelopedandmaintainsaGlobalCurricularFrameworkforthoraciccancer,categorizedaccordingtorelevantsubspecialtiesoftheIASLCmembership.EachofthesesubspecialtycurriculawasbasedonthestructureoftheIASLC-sponsoredTextbookofThoracicOncology.Thiscurriculum-basedframeworkisdesignedtoserveasafoundationfora“lifelonglearning”cultureintheIASLC.ItisenvisionedthateveryIASLC-sponsorededucationaleventwillbealignedwiththiscurricularframework,asitwillbeusedprospectivelytoidentifyeducationgaps,andtoplananddevelopmaterialsforworkshops,webinars,andIASLC-sponsoredliveeducationalevents.Thecurricularframeworkwillalsoserveasthereferenceclassificationsystem(ortaxonomy)fortheplannedIASLCon-lineeducationportal,wheresubspecialtycurriculawillbeusedtoorganizecontentandtagmaterials.Thiscurriculum-orientededucationportalwillalsoprovidecentralizedaccesstoarchivedliveanddistancelearningactivities,aswellasperformanceimprovementCMEmodules.Formoreinformation,pleasevisitiaslc.org.
Global Curricular Framework Categories: » Basic/TranslationalScience » MedicalOncology » Pathology
» PulmonaryMedicine » RadiationOncology » ThoracicSurgery
19ANNUAL REPORT 2015
PublicationsThepastyearsawseveraloftheIASLC’sinitiativescometofruition.Wepubliclyunveiledthesenewpublicationsatthe16thWorldConferenceonLungCancerinSeptember.Allwillhelpusinourmissiontospreadbestpracticesaroundtheglobeandassisthealthprofessionalsintheirbattletoconquerthoraciconcologyworldwide.
New Staging SystemAsannouncedattheWCLC,thepublicationoftheEighthEditionoftheTumor,NodeandMetastasis(TNM)ClassificationofLungCancerwillprovidephysiciansaroundtheworldaccesstonewdatatomorepreciselystageandtreatcasesoflungcancer.Thedata,collectedbytheIASLCStagingCommittee,areplannedforpublicationin2016.
TheIASLChelpedpublishcardsthatexplainthedifferentpartsofthenewstagingsystemandwidelydistributedthemattheWCLC.
In1998,IASLCestablisheditsLungCancerStagingProject,anefforttocollectasignificant,internationaldatabaseoflungcancercasesandtheiranatomicalclassifications.IASLCcollectedandpublishedalargeamountofdataregardingthesizeoftumors,lymphnodeinvolvementandmetastaticstatuswhichwasthenpresentedtotheUnion
forInternationalCancerControl(UICC)andtheAmericanJointCommitteeonCancer(AJCC)forevaluation.BeforetheIASLCStagingProject,datacollectedforstagingoflungcancercamefromasmallergroupofpatients,almostexclusivelybasedintheU.S.
Thenewdatabase,whichwillinformtheEighthEditionoftheTNMClassificationofLungCancer,consistsof94,708patientsdiagnosedaroundtheworldfrom1999-2010.TheobjectiveistofurtherexploreandanalyzetheimpactonprognosisoftumorsizeandofthedifferentTdescriptors;theprognosticsignificanceoftumorburdeninhilarandmediastinallymphnodes;andtheconfirmationoftherevisedM1categories(M1aandM1b)oftheseventheditionoftheclassificationalongwiththeprognosticimpactofnumberandanatomiclocationofmetastases.
Thepreciseclinicaldescriptionofmalignantneoplasmsandhistopathologicalclassificationmayserveanumberofrelatedobjectives:
» Toaidtheclinicianintheplanningoftreatment
» Togivesomeindicationofprognosis
» Toassistinevaluationoftheresultsoftreatment
» Tofacilitatetheexchangeofinformationbetweentreatmentcenters
» Tocontributetothecontinuinginvestigationofhumancancer
20IASLC
AnalysesofthenewdatabaseandthefindingssuggestingrecommendationsfortherevisionoftheseventheditionoftheTNMclassificationoflungcancerwillbesubmittedtotheJournal of Thoracic Oncology to makethemavailabletotheworldwideoncologycommunity.ThesuggestedrecommendationsandtheirsupportivedatawillalsobesubmittedtotheUICCandtheAJCCfortheirassessmentandinclusionintheirnewstagingmanuals,duetobepublishedin2016.TheneweditionoftheclassificationwillthenbeenactedinJanuary2017.
2015 WHO Pathology ClassificationAnadditionalIASLCglobalinitiativeshowcasedattheWCLCincludedthereleaseofthe2015 WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart (Fourth edition).WHOClassificationsrepresentapathologicandgeneticclassificationandgradingofhumantumorsdesignedtobeacceptedandusedworldwide.Theyprovidestandardcriteriaforpathologydiagnosis,clinicalpractice,cancerregistration,epidemiologicstudies,clinicaltrialsandcancerresearch.
The2015WHOClassificationofLungTumorsrepresentstheculminationofadecadeofremarkableadvancesinalllungcancerspecialtiesincluding:pathology(histology,cytology,immunohistochemistry,moleculartesting),clinicaloncology,epidemiology,radiologyandgenetics.Therapidexpansionofmolecularandimmunohistochemicaltoolsprovidedastrongfoundationfortheclassificationandarationaleforreclassificationofspecificentities.
Accuratepathologicdiagnosisandtissuemanagementisnowcriticalinlungcancerdiagnosisandmanagement.Historically,pathologistswerechargedwithdistinguishingbetweensmallcellcarcinomaandnon-smallcellcarcinoma,limitingtheirrole.Withtherapeuticandgeneticadvances(particularlyregardingtargetedtherapiesinpatientswithdrivermutationsinEGFR,ALK,ROS1,BRAFandRET)wheretreatmentstrategiesdependonhistologyandgenetics,pathologistsmustnowmakemoreprecisediagnosesandpreservetissueformoleculartesting.
PreviousWHOclassificationsdidnotfocusondiagnosisinsmallbiopsiesandcytology,sothisisacompletelynewaspecttothisWHOClassification.Criticalaspectsofthisinclude:
» Newdiagnosticcriteriaandterminologyforlungcancerinsmallbiopsiesandcytology
» Moreaccuratehistologicsubtyping
» Strategicmanagementofsmalltissues
» Streamliningworkflowformoleculartesting
» Localmultidisciplinarystrategyforobtaining,processingandreportingthesespecimens.
21ANNUAL REPORT 2015
New Statement on Tobacco Control & Smoking CessationStemmingfromthefactthatthevastmajorityoflungcancercasesresultfromtobaccosmoking,theIASLCissuedanewstatementonTobaccoControlandSmokingCessationattheWCLC.Thestatementcallsforhighertaxesontobaccoproducts,comprehensiveadvertisingandpromotionbansofalltobaccoproductsandproductregulationincludingpackwarnings.
Asakeypartofthestatement,theIASLCTobaccoControlandSmokingCessationCommitteehighlightedanestimatethatshowedthatdoublingtheinflation-adjustedpriceofcigarettescouldresultina33percentreductioninsmokingprevalence.Manylow-andmiddle-incomecountriescanaccomplishthisbytriplingthespecificexcisetaxontobacco.Alow-specificexcisetaxontobaccoisthemainreasoncigarettesareabout70percentcheaperinmanylow-incomecountriescomparedwithhigh-incomecountries.
Inthestatement,theIASLCurgesitsmembersandothersaroundtheworldto:
» JointogethertoforcefullyimplementtheWHO’sFrameworkConventiononTobaccoControlwhichhasamongitskeyprovisionsincreasingcigarettepricesviataxation(toatleast70percentoftheretailprice),prohibitingthesaleofcigarettestominors(lessthan21yearsofage),enactingandenforcingcomprehensivecigarettemarketingpolicies,eliminatingtobaccouseinpubliclocations,mandatinggraphicwarninglabelsoncigarettecontainers,implementingpubliceducationcampaignstodiscouragetheuseofcigarettesandprovidingtobaccocessationsupport.
» Adoptlegalreformsthatallowpeoplewhosmokeandtheirfamiliestousethejudicialsystemtoholdtobaccomanufacturerscivillyandcriminallyaccountableforsellingproductsthataredeadlywhenusedasintended.
» Supportprogramstopreventsmokinginitiationhabitsinchildrenandinyouthandrecognizethatanyattemptstoinducenicotineconsumptioninthispopulationshouldbeavoided.
» Implementtobaccocessationprogramsintheirclinics,hospitalsandcancercenterstoassisttheirpatientsinachievingthebestpossibleoutcomesfromtheircancertreatment.
» Adoptpolicymeasuresthatrecognizetheprobabledifferencesinthelungcancerriskofalternativenicotinedeliveryproducts.Adoptingpoliciesthatfavorlessdangerous(non-combustible)formsofnicotinedeliveryovercigaretteswouldprovideapowerfulincentiveforpeoplewhosmoketomoveawayfromcigaretteswhichinturnwouldhaveaprofoundimpactongloballungcancerratesinthecomingdecades.
ReadthefullStatementonTobaccoControlandSmokingCessationat www.iaslc.org/research-education/policies.
22IASLC
Alex A. Adjei, MD, PhD, FACP, Editor-in-ChiefVolume 11, Number 1, January 2016
Journal ofThoracic Oncology
Of cial Publication of the International Association for the Study of Lung Cancer www.jto.org
JTHO_v11_i1_COVER.indd 1 08-12-2015 15:53:40
Journal of Thoracic OncologyTheJournal of Thoracic Oncology,theofficialjournaloftheIASLC,istheprimaryeducationalandinformationalpublicationfortopicsrelevanttothedetection,prevention,diagnosis,andtreatmentofthoracicmalignancies.JTOemphasizesamultidisciplinaryapproach,andincludesoriginalresearch(clinicaltrialsandtranslationalorbasicresearch),reviews,andopinionpieces.Ithasaglobalauthorbaseandreadershipconsistingofepidemiologists,medicaloncologists,radiationoncologists,thoracicsurgeons,pulmonaryspecialists,radiologists,pathologistsandresearchscientistswithaspecialinterestinthoraciconcology.
In2015,913originalresearcharticlesweresubmittedwithacceptanceof133,resultinginanacceptancerateof14.6percent.Forallsubmissiontypes,therewere1,276manuscriptssubmittedand216wereaccepted,equatinganacceptancerateof16.9percent.Therewere193,387full-textviewsand240,207websitevisitsin2015.The
JTOwasranked30outof211foroncologyand7outof57forrespiratorysystemsubjectmattercategoriesinthe2014JournalCitationReports.The2014ImpactFactorwas5.282,downslightlyfrom5.8in2013.The2015ImpactFactorissettobereleasedinJuly2016.
Startingin2016,ElsevierbecomesthenewpublisheroftheJTO.Alongwithanewlook,themovemakesmanynewfeaturesavailabletoourauthorsandreaders:
» ShareLinkallowsauthorstofreelydistributetheirpublishedarticlesfor50days
» ArticleswillbeaddedtoScopus,theworld’slargestabstractandcitationdatabaseof peer-reviewedliterature
» Acceptedmanuscriptswillbepostedwithinthreedaysofacceptance
» Publishedfindingscanbehighlightedwithaudioslidepresentations.
“Astheleadinginternationallungcancerassociation,theIASLCisexcitedtoexpandthereachoftheJTOandtoensurethatmedicalprofessionalsaroundtheworldhaveaccesstothecuttingedgeresearchbeingsharedinthispublication,”saidAlexA.Adjei,MD,PhD,Editor-in-ChiefoftheJTO.“WeareworkingcloselywiththeElsevierteamtomaximizethebenefitsthatElseviercanprovidetoauthorsandreadersoftheJTO.ThiswillallowustotakeadvantageofsynergieswithElsevier’selectronicinfrastructureandextensivecatalogofleadingcancerpublications.”
23ANNUAL REPORT 2015
TheCommunicationsCommittee,MurryWynes,PhD,andtheIASLCScienceDepartmentcontinuetheireffortstopromotetheJTOthroughpressreleasessenttothemedia.ThiscollaborationhasresultedincoverageinThe New York TimesandotherpremieroutletsthusfurtheringtheeducationaloutreacheffortsoftheIASLC.ThenextpagesshowtheJTOarticlesfeaturedin2015.
JTO Articles Highlighted in Press Releases
Re-evaluation of the role of post-operative radiotherapy and the impact of radiation dose for non-small cell lung cancer using the National Cancer Database
ChristopherD.Corso,MD,PhD;CharlesE.Rutter,MD LynnD.Wilson,MD;AnthonyW.Kim,MD;RoyH.Decker,MD,PhD;ZainA.Husain,MD
Supportive care in lung cancer: Milestones over the past 40 years AlexMolassiotis,RN,PhD;WilmaUyterlinde,NP,PhD;PatriciaJ.Hollen,PhD,RN,FAAN; LindaSarna,RN,PhD;PatriciaPalmer,RN,MS,AOCNS;MeinirKrishnasamy,RN,PhD
Perception of Lung Cancer Among the General Population and Comparison With Other Cancers JulienMazières,MD,PhD;Jean-LouisPujol,MD,PhD;NikosKalampalikis,PhD;DianeBouvry,MD;ElisabethQuoix,MD,PhD;
ThomasFilleron,MD,PhD;NathalieTargowla,MD;DeniseJodelet,PhD;JulieMilia,PhD;BernardMilleron,MD
Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study
MarcoLoIacono,PhD;ValentinaMonica,PhD;LuisellaRighi,MD;FedericaGrosso,MD;RobertaLibener,MD;SimonaVatrano,BS; PaoloBironzo,MD;SilviaNovello,MD;LoredanaMusmeci,MD;MarcoVolante,MD;MauroPapotti,MD;GiorgioV.Scagliotti,MD
Cost-Effectiveness of Multiplexed Predictive Biomarker Screening in Non-Small Cell Lung Cancer DorothyRomanus,PhD;StephanieCardarella,MD;
DavidCutler,PhD;MaryBethLandrum,PhD;NealI.Lindeman,MD;G.ScottGazelle,MD,PhD
24IASLC
Baseline characteristics and mortality outcomes of NELSON control group participants and eligible non-responders UraujhYousaf-Khan,MD;NandaHoreweg,PhD,MD;CarlijnvanderAalst,PhD; KevintenHaaf,MSc;MathijsOudkerk,PhD,MD;HarrydeKoning,PhD,MD
Distinct epidemiology and clinical consequence of classic versus rare EGFR mutations in lung adenocarcinoma
ZoltanLohinai,MD;MirAlirezaHoda,MD;KatalinFabian,MD;GyulaOstoros,MD,PhD;ErzsebetRaso,PhD; TamasBarbai,MS;JozsefTimar,MD,PhD,DSc;IlonaKovalszky,MD,PhD;MihalyCserepes,MS;AnitaRozsas,MS; ViktoriaLaszlo,PhD;MichaelGrusch,PhD;WalterBerger,PhD;WalterKlepetko,MD;JuditMoldvay,MD,PhD;
BalazsDome,MD,PhD;BalazsHegedus,PhD
The presence of asbestos in the natural environment is likely related to mesothelioma in young individuals and women from Southern Nevada
FrancineBaumann,PhD;BrendaJ.Buck,PhD;RodneyV.Metcalf,PhD; BrettT.McLaurin,PhD;DouglasJ.Merkler,MSc;MicheleCarbone,MD,PhD
Impact of an Interactive Online Tool on Therapeutic Decision-Making for Patients with Advanced Non-Small Cell Lung Cancer
HelenChow,MD;MartinJ.Edelman,MD;GiuiseppeGiaccone,MD;SureshS.Ramalingam,MD;TimothyA.Quill,PhD; AndrewD.Bowser,PhD;JimMortimer,PhD;WilmaGuerra,PhD;LaurelA.Beckett,PhD;
HowardL.West,MD;PrimoN.Lara,MD;DavidR.Gandara,MD
Patients selected for definitive concurrent chemoradiation at high-volume facilities achieve improved survival in stage III non-small cell lung cancer
ElynH.Wang,BS;CharlesE.Rutter,MD;ChristopherD.Corso,MD,PhD;RoyH.Decker,MD,PhD; LynnD.Wilson,MD,MPH;AnthonyW.Kim,MD;JamesB.Yu,MD,MHS;HenryS.Park,MD,MPH
Randomised study on early detection of lung cancer with MSCT in Germany: results of the first 3 years of follow-up after randomization
N.Becker,PhD;E.Motsch,MD;M.-L.Gross,MD;A.Eigentopf,BSc;C.P.Heussel,MD,PhD;H.Dienemann,MD,PhD; P.A.Schnabel,MD,PhD;M.Eichinger,MD;D.-E.Optazaite,MD;M.Puderbach,MD,PhD;
M.Wielpütz,MD;H.-U.Kauczor,MD,PhD;J.Tremper,MD;S.Delorme,MD,PhD
FDG Uptake on Positron Emission Tomography Correlates with Survival and Time to Recurrence in Patients with Stage I Non-Small Cell Lung Cancer
WoocheolKwon,MD;BrandonA.Howard,MD,PhD;JamesE.Herndon,PhD;EdwardF.Patz,Jr.MD
Increasing Physical Activity and Exercise in Lung Cancer: Reviewing Safety, Benefits, and Application BrettC.Bade,MD;D.DavidThomas,MS;JoAnnB.Scott,BA;GerardA.Silvestri,MD,MS
Hormone use, reproductive history and risk of lung cancer: the Women’s Health Initiative Studies AnnG.Schwartz,PhD,MPH;RobertaM.Ray,MS;MicheleL.Cote,PhD;JudithAbrams,PhD;RobertJ.Sokol,MD;
SusanL.Hendrix,DO;ChuChen,MS,PhD;RowanT.Chlebowski,MD,PhD;F.AllanHubbell,MD,MSPH; CharlesKooperberg,PhD;JoAnnE.Manson,MD,DrPH;MaryJoO’Sullivan,MD,DrPH;ThomasRohan,MBBS,PhD;
MarciaL.Stefanick,PhD;JeanWactawski-Wende,PhD;HeatherWakelee,MD;MichaelS.Simon,MD,MPHS
25ANNUAL REPORT 2015
Implementation of amplicon parallel sequencing leads to improvement of diagnosis and therapy of lung cancer patients
KatharinaKönig,PhD;MartinPeifer;JanaFassunke,PhD;MichaelaA.Ihle,Dipl-Biol;HelenKünstlinger,Dpil-Biol; CarinaHeydt,MSc;KatrinStamm,PhD;FrankUeckeroth;ClaudiaVollbrecht,BSc;MarcBos,MD;MasyarGardizi,MD;
MatthiasScheffler,MD;LuciaNogova,MD;FraukeLeenders,MD;KerstinAlbus,MSc;LydiaMeder,MSc; KerstinBecker,PhD;AlexandraFlorin,MA;UrsulaRommerscheidt-Fuss;JanineAltmüller,PhD;
MichaelKloth,MD;Nürnberg,PeterProf;ThomasHenkel,PhD;Sven-ErnöBikár,PhD;MartinL.Sos,PhD; WilliamJ.Geese,PhD;LewisStrauss;Yon-DschunKo,MD;UlrichGerigk,MD;MargareteOdenthal,PhD;
ThomasZander,MD;JürgenWolf,Prof;SabineMerkelbach-Bruse,MD; ReinhardBuettner,MD;LukasC.Heukamp,PhD,MD
Tobacco Cessation May Improve Lung Cancer Patient Survival KatharineA.DobsonAmato,MPH,PhD;AndrewHyland,PhD;RobertReed,MPH;MartinC.Mahoney,MD,PhD;
JamesMarshall,PhD;GaryGiovino,PhD;MaansiBansal-Travers,PhD;HeatherM.Ochs-Balcom,PhD;MichaelA.Zevon,PhD; K.MichaelCummings,PhD;ChukwumereNwogu,MD,PhD;AnuragK.Singh,MD;HongbinChen,MD,PhD;
GrahamW.Warren,MD,PhD;MaryReid,PhD
Safety and Efficacy of Buparlisib (BKM120) in Patients With PI3K Pathway-Activated Non-Small Cell Lung Cancer (NSCLC): Results From the Phase II BASALT-1 Study
JohanF.Vansteenkiste,MD,PhD;Jean-LucCanon,MD;FilippoDeBraud,MD;FrancescoGrossi,MD;TommasoDePas,MD; JhanelleE.Gray,MD;Wu-ChouSu,MD;EnriquetaFelip,MD,PhD;HiroshigeYoshioka,MD;CesareGridelli,MD;
GraceK.Dy,MD;SumitraThongprasert,MD;MartinReck,MD,PhD;PaolaAimone,MD;GenaAtallaVidam,MS,CPM; PanteliaRoussou,PhD;YingA.Wang,PhD;EmmanuelleDiTomaso,PhD;Jean-CharlesSoria,MD,PhD
Profiling of oncogenic driver events in lung adenocarcinoma revealed MET mutation as independent prognostic factor
SaiF.Yeung,BSc;JoannaTong,H.M.PhD;PeggyLaw,P.W.MPhil;LauY.Chung,AD;Lung,W.M.RaymondPhD; CarolTong,Y.K.MPhil;ChitChow,PhD;AnthonyChan,W.H.FRCPA;InnesWan,Y.P.FRCS;
TonyMok,S.K.MD;KaF.To,FRCPA
Monotherapy Administration of Sorafenib in Patients With Non–Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non–Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens
LuisPaz-Ares,MD;VeraHirsh,MD;LiZhang,MD;FilippodeMarinis,MD;JamesChih-HsinYang,MD; HeatherA.Wakelee,MD;TakashiSeto,MD;Yi-LongWu,MD;SilviaNovello,MD;ErszébetJuhász,MD;OsvaldoArén,MD;
YanSun,MD;ThomasSchmelter,PhD;TengJinOng,MD;CarolPeña,PhD;EgbertF.Smit,PhD;TonyS.Mok,MD
26IASLC
Fred R. Hirsch WCLC2015Congress
PresidentUniversityofColorado
James JettWCLC2015Congress
Co-ChairNationalJewishHealth
Harvey PassWCLC2015Congress
Co-ChairNYULangone MedicalCenter
Everett Vokes WCLC2015Congress
Co-ChairTheUniversityofChicagoMedicine
President and Co-Chairs
MeetingsIASLCmembersandstaffworktoenhancetheunderstandingoflungcanceramongscientists,membersofthemedicalcommunityandthepublic.Oneofthemosteffectivewaysthatthisisaccomplishedisbyofferingcutting-edgeeducationalmeetingsaroundtheglobe.
The16thWorldConferenceonLungCancer(WCLC),heldSept.6-9inDenver,Colorado,wasahugesuccess.
2015 IASLC World Conference on Lung CancerIASLC’sbannereventof2015wasthe16thWorldConferenceonLungCancer(WCLC)heldinDenver,Colorado,USAinearlySeptember.Morethan6,000researchers,physiciansandspecialistsfromnearly100countriescametogethertolearnandshareinformationaboutlungcancer.
Theconferenceistheworld’slargestmeetingdedicatedtolungcancerandotherthoracicmalignanciesandcoversawiderangeofdisciplines,includingmorethan300invitedtalksand3,000formalresearchstudiesandclinicaltrialresults.EverypresentationateachWCLCaimstoincreaseawarenessandcollaborationsosurgeons,medicaloncologists,radiationoncologists,pulmonologists,radiologists,pathologists,epidemiologists,basicresearchscientists,nurses,alliedhealth
professionals,advocates,caregiversandpatientsunderstandthelatestdevelopmentsandcanimplementthemthroughouttheworld.
WELCOME TO THE IASLC
16TH WORLD CONFERENCE ON LUNG CANCER
Conference Program Book
FOLLOW US ON TWITTER @IASLC #WCLC2015
FOLLOW US ON FACEBOOK
WWW.IASLC.ORG
BECOME A MEMBER OF IASLC VISIT WWW.IASLC.ORG
27ANNUAL REPORT 2015
DaraAisner UniversityofColorado
BrianKavanagh UniversityofColorado
AnnaBaron UniversityofColorado
RobertKeith UniversityofColorado
PaulA.Bunn,Jr. UniversityofColorado
JeffreyKern NationalJewishHealth
TimByers UniversityofColorado
EviMakovsky PatientAdvocate
D.RossCamidge UniversityofColorado
DanMerrick UniversityofColorado
LaurieCarr NationalJewishHealth
YorkMiller UniversityofColorado
RobertDoebele UniversityofColorado
JohnMitchell UniversityofColorado
WilburFranklin UniversityofColorado
AnaOton UniversityofColorado
MarileilaVarella-Garcia UniversityofColorado
DavidRaben UniversityofColorado
KavitaGarg UniversityofColorado
MichaelWeyant UniversityofColorado
LaurieGaspar UniversityofColorado
SamirWitta MountainBlueCancerCareCenter
RobertJotte RockyMountainCancerCenters
Local Organizing Committee
Forthefirsttime,thisyear’sconferenceincludedlungcancerpatients,survivorsandcaregivers.Additionally,theconferencesawthereleaseofIASLC’snewTobaccoControlandSmokingCessationStatement(seepage21)andtheculminationoftwomajorIASLCinitiatives:theEighthEditionoftheTumor,NodeandMetastasis(TNM)ClassificationofLungCancer(page19)andThe WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart (Fourthedition)(page20).
ThisWCLCalsofeaturedthefirsteverFunWalkandPancakeBreakfast.Around300peopleparticipated,includinglungcancerpatients,healthprofessionals,patientadvocatesandmore.Theeventraisednearly$20,000fortheIASLCFoundation.
The2015WCLCalsomarksthebeginningofanewerafortheIASLC.Insteadofeverytwoyears,wewillnowhosttheWCLCannually.The17thWCLCissettotakeplaceinDecember2016inVienna,Austria,andthe18thWCLCwillbeinYokohama,JapaninOctober2017.
28IASLC
WCLC 2015 By the Numbers » More than 6,000 attendees » From nearly 100 countries » 2,122 abstracts submitted » 258 oral abstracts presented » 437 mini-oral abstracts presented » 1,213 poster presentations » 89 invited sessions
Medical Oncology
Other
Thoracic Surgery
Pulmonary Medicine
Cancer Research
Radia�on Oncology
Nursing
Pathology
Basic Sciences
Pharmacy
Diagnos�c Radiology
Advocacy
Biosta�s�cs
Hermatology
Smoking Cessa�on
0%
10%
20%
30%
40%
50%
60%
Europe North America Asia Rest of the World
Medical Oncology
Other
Thoracic Surgery
Pulmonary Medicine
Cancer Research
Radia�on Oncology
Nursing
Pathology
Basic Sciences
Pharmacy
Diagnos�c Radiology
Advocacy
Biosta�s�cs
Hermatology
Smoking Cessa�on
0%
10%
20%
30%
40%
50%
60%
Europe North America Asia Rest of the World
Demographic Distribution
Specialties of Delegates
Medical Oncology
Other
Thoracic Surgery
Pulmonary Medicine
Cancer Research
Radia�on Oncology
Nursing
Pathology
Basic Sciences
Pharmacy
Diagnos�c Radiology
Advocacy
Biosta�s�cs
Hermatology
Smoking Cessa�on
0%
10%
20%
30%
40%
50%
60%
Europe North America Asia Rest of the World
29ANNUAL REPORT 2015
Best of IASLC WCLC 2015
Location Date Organizer/ChairTurin,Italy September2015 SilviaNovello
Florence,Italy September2015 SilviaNovello
Bari,Italy September2015 SilviaNovello
SanFrancisco,USA October2015 DavidGandara
Paris,France October2015 ThierryleChevalier
Oslo,Norway October2015 OddTerjeBrustugun
TheNetherlands October2015 QuadiaGroup
Guangdong,China October2015 ChineseThoracicOncologyGroup
Yokohama,Japan November2015 JapanLungCancerSociety
Prague,CzechRepublic November2015 CentralEuropeanLungCancerGroup
Salvador,Brazil December2015 LatinAmericanCooperativeGroup
Athens,Greece January2016 KonstantinosSyrigos
Seoul,Korea January2016 KeunchilPark
Lima,Peru February2016 GrupodeEstudiosClinicoPeruano
BuenosAires,Argentina March2016 EduardoRichardet
Cancun,Mexico March2016 MauroMolinaVargas
Best of WCLC 2015ForthosenotabletoattendtheWCLC,IASLCcontinuestogrowandexpandthe“BestofWCLC”events–educationalinitiativeswhichcondensethetimeliestscientificandeducationaltopicsfrommultipledisciplinesintoaone-dayeventandheldthroughouttheworldin2015.IASLCpartneredwithlocalexpertswhocraftedtheagendasandfocusedonWCLCcontenttomeettheirregionalneeds.
30IASLC
IASLC Meetings in 201515th Annual Targeted Therapies of the Treatment of Lung CancerThisinvitation-onlymeetinggatheredthetopscientiststodiscussthelatestadvancesinthetreatmentoflungcancerwithtargetedtherapies.February 18 – 21, 2015 | Santa Monica, CA Chairs:PaulA.Bunn,Jr.,DavidH.Johnson andRoyHerbst#Participants:450
European Lung Cancer Conference (ELCC)TheEuropeanSocietyofMedicalOncology(ESMO)andtheIASLCorganizedtheELCC,bringingtogetherthetopacademicexpertsinlungcancerandthoracicmalignanciestoshowcasethelatestdevelopmentsinbasic,clinicalandtranslationalresearch.
April 15-18 2015 | Geneva, Switzerland Chairs:DominiqueGrunenwald,FranceandJohanVansteenkiste,Belgium#Participants:1650
Small Cell Lung Cancer TwohundredglobalexpertsinSCLCmettoreviewandrefocusthefield,tofostercollaborationwiththegenerationofnewandinnovativeideasforbasicandclinicalresearch,andtohighlightthepotentialroleforpersonalizedmedicineinSCLCclinicaltrialdesigns.Areviewpublicationfromthismeetingwillbepublishedin2016.April 22-24, 2015 | New York, NYChairs: CharlesRudin,FredR.Hirsch,PaulA.Bunn,Jr.,JohnMinna,GlenwoodGoss,RomanThomas,PeterUjhazy,WolfLindwasser,andShakunMalik#Participants:200
EGFR Expert MeetingAgroupofmultidisciplinaryexpertsincludingpathologists,pulmonologists,medicaloncologists,thoracicsurgeons,radiationoncologists,anddiagnosticradiologistsmettodiscusshowbesttoguidethelungcancercommunitiesonmoleculartestingandclinicalmanagementofpatientswithEGFRmutatedNSCLC,whohaveprogressedonfirst-lineEGFRTKItherapyforadvanceddisease.August 1, 2015 | Huntington Beach, CAChair: FredR.Hirsch#Participants:20
31ANNUAL REPORT 2015
BTOG 2015BritishThoracicOncologyGroup(BTOG)13thAnnualConferenceJanuary 28-30, 2015 | Dublin, Ireland
2015 Lung Cancer Workshop XIIPreventCancerFoundationMay 4-5, 2015 | Bethesda, MD
23rd European Conference on General Thoracic SurgeryEuropeanSocietyofThoracicSurgeonsMay 31-June 3, 2015 | Lisbon, Portugal
16th Annual International Lung Cancer CongressJuly 30 - August 1, 2015 | Huntington Beach, CA
4th Congress of Respiratory MedicineInstituteforPulmonaryDiseasesofVojvodinaMedicalFaculty,UniversityofNoviSadandClinicforPulmonology, ClinicalCenterofSerbiaOctober 15-18, 2015 | Novi Sad, Serbia
Eighth Annual Symposium on Personalized Therapies and Best Clinical Practices for Lung CancerBioMedicalLearningInstitute(BMLI)October 17, 2015 | San Francisco, CA
International Conference on Mesothelioma in Populations Exposed to Naturally Occurring Asbestiform FibersChairman:MicheleCarboneNovember 9-10, 2015 | Honolulu, HI
CELCC 201515thCentralEuropeanLungCancerConferenceNovember 28-30 2015 | Prague, Czech Republic
IASLC Endorsed and Supported Meetings in 2015
32IASLC
Inter-Disciplinary Workshop to Enhance Assessment and Management of Lung CancerIDEALWorkshopDecember 4, 2015 | Singapore
9th Annual ConferencePolishLungCancerGroupNovember 6-7, 2015 | Warsaw, Poland
2nd International Conference AsiaThoracoscopicSurgeryEducationProgram(ATEP)December 4-5, 2015 | Seoul, Korea
4th AACR-IASLC International Joint ConferenceThetranslationalsciencefeaturedatthisconferencewillincludethefoundationofbasicresearchthatbeginsatthebenchandcontinuesthroughpatientcareintheclinic.January 4 – 7, 2016 | San Diego, CA Moredetailsonwww.iaslc.org
16th Annual Targeted Therapies of the Treatment of Lung CancerThisinvitation-onlymeetinggathersthetopscientiststodiscussthelatestadvancesinthetreatmentoflungcancerwithtargetedtherapies.February 17 – 20, 2016 | Santa Monica, CA Moredetailsonwww.iaslc.org
European Lung Cancer Conference (ELCC)TheEuropeanSocietyofMedicalOncology(ESMO)andtheIASLCorganizetheELCC,bringingtogetherthetopacademicexpertsinlungcancerandthoracicmalignanciestoshowcasethelatestdevelopmentsinbasic,clinicalandtranslationalresearch.April 13-16 2016 | Geneva, Switzerland Moredetailsonwww.iaslc.org
2016 Meetings and Events
33ANNUAL REPORT 2015
IASLC Asia Pacific Lung Cancer Conference (APLCC 2016)Theconferencewillbringyouinformationinfrontiersofclinicalandbasicresearches,practicalclinicalmanagement,andmultidisciplinarycarefromWesternandAsia-Pacificfaculties.May 13 - 16 2016 | Chiang Mai, Thailand Moredetailsonwww.iaslc.org
2016 IASLC Latin American Lung Cancer Conference (LALCA)InternationalandnationalspeakerswilldiscussthescienceandadvancesinthetreatmentandpreventionoflungcancerandthoracicmalignanciesworldwideandinLatinAmericainparticular.August 25 - 27 2016 | Panama City, Panama Moredetailsonwww.iaslc.org
IASLC Chicago Multidisciplinary Symposium in Thoracic OncologyCo-chairs: FredR.Hirsch,MD,PhD& EverettVokes,MD.September 22-24 2016 | Chicago, IL Moredetailsonwww.iaslc.org
17th IASLC World Conference on Lung CancerTheWorldConferenceonLungCancer(WCLC)istheworld’slargestmeetingdedicatedtolungcancerandotherthoracicmalignancies.Morethan6,000delegatescomefromnearly100countriestodiscussthelatestdevelopmentsinthoracicmalignancyresearch.
December 4-7 2016 | Vienna, Austria Moredetailsonwww.iaslc.org
34IASLC
TheMary J. Matthews Pathology/Translational Research AwardisgiventoanIASLCscientistforlifetimescientificachievementsinpathology-translationalresearchofthoracicmalignancies.Dr.MingTsaoreceivedthisawardfor2015. Dr.Tsao’sprimarygoalinlungcancerresearchistoidentifygenesorproteinsthatarepredictiveofpoorprognosisinlungcancerpatientswhohavehadtheirtumorsresectedbysurgery.Hiscurrentlungcancerresearchactivitiesincludebiomarkersintargetedcancertherapy,molecularprognosticandpredictivemarkersandpathobiologyoflungcancer,tumorcellstromalinteraction,Rasoncogene,andapplicationofnoveloptical/Ramantechnologiesfortissue/cellularandinvivoimaging.Dr.TsaohasservedontheEditorialBoardoftheJTOandasamemberoftheInternationalProgramCommitteeforthreeWCLCs.
TheJoseph W. Cullen Prevention/Early Detection AwardisgiventoanIASLCscientistforlifetimescientificachievementsinpreventionresearchofthoracicmalignancies.Dr.JacekJassemheadstheDepartmentofOncologyandRadiotherapyattheMedicalUniversityofGdansk,Poland.Hisdepartment’sresearchunitfocusesonclinicaltrialsandtranslationalresearchcombiningcancermolecularfeatureswithclinicalbehavior.Theteamhasdevelopedandvalidatednoveltumorbiomarkersinlungcancerandbreastcancer,andsharesalongtermcollaborationwiththeUniversityofColorado,publishinginthefieldofpredictiveassaysforthepotentialbenefitsoftargetedtherapiesinlungcancer. Dr.JassemisamemberoftheIASLCTobaccoControlandSmokingCessationCommitteeandactivelyadvisesothercountriesonthistopic.
IASLC 2015 Distinguished AwardsTheIASLChasfourdistinguishedawardswhichwerepresentedatthe2015WorldConference onLungCancer(WCLC).
ThePaul A. Bunn, Jr. Scientific AwardisgiventoanIASLCscientistforlifetimescientificcontributionsinthoracicmalignancyresearchandwhohasalsocontributedtotheorganization’sdevelopment.Dr.Yi-LongWu’smainresearchinterestsarethemultidisciplinarysynthetictherapyonlungcancerfrombasicsciencetobedsideandevidence-basedmedicineinoncology.Hisresearchmainlyfocusesonclinicalandbasicstudyofcombinedtreatmentofnon-smallcelllungcancer(NSCLC),especiallyinprofilingthelungcancertumorsinChinesepatientsfordriveroncogenesandtobuildatumortissuebankacrossChina,connectedbyacomputersystem.HeisaleaderintheChineselungcancerfieldandhasbeenaPrincipalInvestigatororCo-PIinmorethan90multi-centerclinicaltrials.Hehascontributed20booksoncancerandhaspublishedmorethan300articlesinpeer-reviewedjournals.Dr.WualsoservesontheIASLCBoardofDirectors.
The IASLC Merit Award isgiventoamemberofIASLCwhohasmadeanextraordinarycontributiontotheorganization’sdevelopment.Dr.HarveyPassreceivedthe2015IASLCMeritAwardforhisworkasasurgeonscientistfocusingontheearlydetection,surgicalmanagementandadjuvanttherapyofthoracicmalignancies.Dr.PasshasbeencontinuouslyfundedbytheDOD,NCI,andtheCDCamongotherssince1998forthediscoveryandvalidationofblood-basedbiomarkersincludingosteopontin,solublemesothelinrelatedprotein,andfibulin3.Dr.Passhaspublishedover450peer-reviewedpublications,11books,includingtheIASLCMultidisciplinaryApproachtoThoracicOncology,andservesasaneditorandonmanyeditorialboards.Dr.PasshasbeenanactivememberoftheIASLCsince1998,servingasthechairofthePublicationsCommitteeandtheCo-Chairofthe2015WCLCLocalOrganizingCommitteeamonghisotherroles.
Dr. Harvey PassUSA
2015 IASLC Merit Award
Dr. Yi-Long WuChina
Paul A. Bunn, Jr. Scientific Award
Dr. Jacek JassemPoland
Joseph W. Cullen Prevention/Early Detection Award
Dr. Ming TsaoCanada
Mary J. Matthews Pathology/ Translational Research
Award
35ANNUAL REPORT 2015
IASLC WCLC 2015 Developing Nation AwardsAsrecipientsofthe2015DevelopingNationAwards,tenresearchersfromsixdevelopingnationsreceivedsupporttoattendtheWCLCinDenver,Colorado.
Recipient Institution CountryBernadetteReynaAsuncion DeLaSalleUniversity PhilippinesMaríaCastillo INCan MexicoXiangkunHan ChineseAcademyofSciences ChinaTomiKovacevi InstituteforPulmonaryDiseasesofVojvodina,Facultyof
Medicine,UniversityofNoviSadSerbia
SatyaNarayan AcharyaTulsiRegionalCancerTreatmentandResearchInstitute IndiaBlessingObiazi-Odiase ChildrenLifeAdvancementProject NigeriaEmmanuelOdiase NigerianCancerSociety NigeriaCristinaPerez NationalCancerInstituteofBrazil BrazilMalcolmTagbarha UniversityofAbuja NigeriaQiWang TheSecondAffiliatedHospitalofDalianMedicalUniversity China
IASLC WCLC 2015 Young Investigator AwardsIASLCYoungInvestigatorAwardsaregiventorewardscientificexcellenceandtoencourageinnovativeresearchinlungcancerpreventionandtranslationalmedicineworldwide.TheawardsareopentoIASLCmemberswhoarewithinthreeyearsofaninitialfacultyappointmentatthetimeofapplicationandwithinthreeyearsofcompletionoffellowship/postdoctoraltraining.
Recipient Institution CountryLynnetteFernandez-Cuesta InternationalAgencyforResearchonCancer FranceYoshihisaKobayashi KinkiUniversityFacultyofMedicine JapanJiYunLee SamsungMedicalCenter SouthKoreaClaraPérez-Rambla CentrodeInvestigaciónPríncipeFelipe SpainTomaszPowrózek MedicalUniversityofLublin PolandBrandonSheffield UniversityofBritishColumbia CanadaKenichiSuda KinkiUniversityFacultyofMedicine JapanDanaTsui UniversityofCambridge EnglandDaweiYang ZhongshanHospitalFudanUniversity ChinaWenjingZhang ChineseAcademyofSciences China
36IASLC
Recipient Role LocationHildrethGrossman President/Founder,UpstageLungCancer Brookline,MassachusettsSedaKansu Co-founder,PembeHanim Istanbul,TurkeyVictorLasebikan PsychiatristandLecturer,UniversityofIbadan Nigeria,AfricaKathleenMewhiney Founder/President,TheJohn&AmyMewhineyCancer
FoundationSilverSpring,Maryland
DanPowell LungCancerSurvivor/PatientAdvocate Greenville,SouthCarolinaTetsuyaYamaoka LungCancerSurvivor/PatientAdvocate Tokyo,Japan
Award Recipient AbstractAdiGazdarLectureshipAward(TranslationalResearch)
LynnetteFernandez-Cuesta,PhD “GenomicCharacterizationofLargeCellNeuroendocrineLungTumors”
RobertGinsbergLectureshipAward(Surgery)
VirginieWesteel,MD “CompliancewithFollow-UpProgramsafterSurgeryforNon-SmallCellLungCancerinthePhaseIIIIFCT-0302Trial”
HeineHansenLectureshipAward(SmallCellLungCancer)
CharlesRudin,MD,PhD “ADLL3-TargetedADC,RovalpituzumabTesirine,DemonstratesSubstantialActivityinaPhaseIStudyinRelapsedandRefractorySCLC”
DanIdheLectureshipAward(MedicalOncology)
JohnEdwards,MD “QualityofResectioninPathologicalN2NSCLCinthePhase3LungAdjuvantRadiotherapyTrial(LungART):AnImportantFactor”
CliftonMountainLectureshipAward(Staging)
EdwardRobbins,MD “EvolutionintheSurgicalCareofNon-SmallCellLungCancer(NSCLC)PatientsintheMid-SouthQualityofSurgicalResection(MS-QSR)Cohort”
TsuguoNarukeLectureshipAward(Surgery)
RyutaroKakinuma,MD “NaturalHistoryofPulmonarySubsolidNodules:AProspectiveMulticenterStudy”
IASLC WCLC 2015 Advocacy Awards
IASLC WCLC 2015 Lectureships
TheIASLCWCLC2015AdvocacyAwardsaredesignedtoincreaseconnectionswithpatientadvocatesandadvocacyorganizationsaroundtheworld.Aninternationalpanelselectedtheawardwinnersfortheirleadershipinsupportinglungcancerresearch,patientsandawarenessworldwide.
TheIASLCrecognizedsixinvestigatorswithIASLCWCLC2015LectureshipAwardsfortheirhigh-rankingabstractsinkeyareasoflungcancer.TheseawardsarenamedafterIASLCmemberswhohavebeenleadersintheirfields.
37ANNUAL REPORT 2015
IASLC would like to thank the following supporters of the IASLC 2015 International Mentorship Award Program:
Astellas • AstraZeneca • Bristol-Myers Squibb • Clovis • Merck • Novartis
IASLC WCLC 2015 International Mentorship AwardsTheInternationalMentorshipProgram,anew2015IASLCinitiative,isaprofessionaldevelopmentand educationprogramforearly-careerphysicians/researchersstudyingthoracicmalignanciesfrom economically-developingcountries.Theawardeesarematchedwithwell-establishedscientificandclinicalmentorsfromwithinthehostingWCLCregionandvisitthementor’sinstitutionforapproximatelyaweekfollowingtheWCLC.
Recipient Country MentorRafaelBitton Brazil SureshRamalingamSaulCamposGomez Mexico CharlesRudinJulianoCeCoelho Brazil RamaswamyGovindanRaniaAly Egypt WilliamTravisMariaJoseLabanca Argentina MarileilaVarella-GarciaZoltanLohinai Hungary PaulA.Bunn,Jr.DanielaMorales-Espinosa Mexico DavidCarboneAhmedNagy Egypt FredR.Hirsch/TheresaBoyleShengxiang“Harry”Ren China RossCamidgeSoumyajitRoy India KavitaGargPhanninTiraswasdichai Thailand AlexAdjeiLongJiang China JohnMitchellRajaramBurrah India JessicaDonington
Mentees with IASLC leadership at WCLC 2015
38IASLC
LungCancerFoundationofAmerican(LCFA)-FellowshipPartner
PreventCancerFoundation-FellowshipPartnerAddarioLungCancerFoundation-FellowshipPartner
AmericanLungAssociation(Colorado)CaringAmbassadorsLungCancerProgram
ChrisDraftFamilyFoundationCliftonF.MountainFoundation
DustyJoyFoundationEX:Re-learnLivewithoutCigarettes
FreeMeFromLungCancerFreetoBreathe
GlobalLungCancerCoalitionGlobalResourceforAdvancingCancerEducation
(GRACE)
InternationalThoracicOncologyNursingForumJohn&AmyMewhineyCancerFoundation
LungCancerAllianceLungCancerResearchFoundation
LungFoundationAustraliaLungevityFoundation
MesotheliomaAppliedResearchFoundationMyCancerGenome
PatientsRisingPembeHanim
UICCGlobalCancerControlCommunityUnionforInternationalCancerControl-UICC
UpstageLungCancerWomenAgainstLungCancerinEurope
AbbVieAriadPharmaceuticals
AstellasPharmaAstraZenecaBiodesix
BoehringerIngelheimBristol-MyersSquibb
CelgeneClovisOncologyDaiichiSankyo
EliLillyElekta
HelsinnTherapeutics
IlluminaJanssenPharma
MerckMyriadNovartisPfizer
Roche/GenentechSyntaPharmaceuticals
VentanaMedicalSystemsVerastemVertex
Pharmaceuticals
2015 SponsorsWe want to thank our sponsors for their generosity and support:
2015 Advocacy Partners
39ANNUAL REPORT 2015
Strategic PlanThe mission of the IASLC is:
» Toembracethestudyoftheetiology,epidemiology,prevention,diagnosis,treatmentandallotheraspectsoflungcancerandotherthoracicmalignancies,
» ToprovideeducationandinformationaboutlungcancerandotherthoracicmalignanciestoIASLCmembers,tothemedicalcommunityatlarge,andtothepublic,and,
» Touseallavailablemeanstoeliminatelungcancerandotherthoracicmalignanciesasahealththreatfortheindividualpatientandthroughouttheworld.
TheIASLCBoardofDirectorsapprovedanambitiousstrategicplanfortheorganizationin2011afterasix-monthprocess.IASLCstaffstilladherestothisplan,eachyearidentifyingnumerousactionitemsrequiredtomakesignificantstepstowardachievingtheplan.In2015,IASLCstaffandmembersconductedtheactivitiesbelowtosupportthestrategicplanand ourmission.
StudyGOAL 1 – IASLC embraces the study of the etiology, epidemiology, prevention, diagnosis, treatment and all other aspects of lung cancer and other thoracic malignancies.
» TheIASLCStagingCommitteedevelopedthe8thEditionoftheStagingofLungCancer.WithnewclassificationsinMesotheliomaandThymicmalignancies,thenewclassificationsarethemostcomprehensiveever.
» TogetherwiththeWHO,theIASLCPathologyCommitteedevelopedthenew2015 WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart (Fourth edition).TheIASLCisalsoworkingonneweditionsoftheAtlasofALKTestinginLungCancerandonaPD-L1Atlastoguideimmunotherapy.
40IASLC
» The2015WorldConferenceonLungCancer(WCLC)inDenverhadthemostcomprehensivetobaccocontrolandsmokingcessationprogramforanyworldconference,andincludedthelaunchoftheTobaccoControl andSmokingCessationCommittee’supdatedIASLCStatementonTobaccoControlandSmokingCessation.TheIASLCsignedontomultiplepolicylettersrelatedtotobaccocontrolin2015.
» TheIASLCPrevention,ScreeningandEarlyDetectionCommitteeheldanall-day,sold-outworkshoponplanningfortheimplementationoflungcancerCTscreeninginternationallyatWCLC2015.Committeemembersalsocreatedastandardizedapproachtoestablishinglungcancerscreeningclinics,toensureworldwideconsistency.Committeememberswroteadocumentonestablishingalungcancerscreeningclinic,withtheaimofhelpingcentersthroughastandardizedapproach.
EducationGOAL 2 - IASLC provides education and information about lung cancer and other thoracic malignancies to IASLC members, to the medical community at large and to the public.
» IASLChostedasuccessfulWorldConferenceonLungCancer(WCLC)inDenver,highlightinggroundbreakingscienceandexpandingattendancetopatientsandadvocatesaswellashealthprofessionals.TheIASLCwillnowhosttheWCLCeveryyear,continuingin2016inVienna,Austria,inYokohama,Japanin2017,inToronto,Canadain2018andinBarcelona,Spainin2019.
» IASLCuseditsrecentaccreditationtoofferexpandedandenhancedCMEatmanyof ourevents.
» IASLCcontinuedtobuilditseducationalwebinars,offeringmorewebinarsonmoretopicsandacrossmoretimezonesthan everbefore.
41ANNUAL REPORT 2015
» TheEducationCommitteedevelopedmultidisciplinarycurriculumforfellowsandyounginvestigators,evaluatedrequestsforIASLCendorsedmeetingsanddevelopedLiveLearningProgramswhichwereinitiatedin2015andwillcontinueinthefuture.
» IASLCinitiatedanewseriesofthe“BestofWCLC”inthefallof2015.Withthehelpoflocalexperts,IASLCprovidedthemostsignificantupdatesfromtheWCLCtohundredsofparticipantsin18internationallocationswhowereunabletoattendtheWCLC inDenver.
» TheIASLC,alongwithExecutiveEditor HarveyI.Pass,MD,initiatedworkonaneweditionoftheIASLCMultidisciplinaryApproachtoThoracicOncologytextbooksetforpublicationin2016.
» » » » » » » » » »
»
Research and ScienceGOAL 3—IASLC advances research and science towards reducing the burden of thoracic malignancies worldwide.
» IASLCcontinuesitsfundingoffellowshipstopromotescientificexcellenceandtoencourageinnovativeresearch.ThisyearIASLCsupported11fellowsinitsprogram,continuedaChinesefellowshipandpartneredwiththeBonnieJ.AddarioFoundationtocreatealargefellowshipforthepreventionandearlydetectionof lungcancer.
» TheIASLCJournal of Thoracic Oncology continuedtoexpanditscoverageofthetoptranslationalandbasicresearchandaddedsignificantlytoitssubscriberbasewhilefinalizingadealwithanewpublisher,Elsevier.Alongwithanewlook,themovemakes manynewfeaturesavailabletoourauthorsandreaders.
» TheJTOwasranked30outof211foroncologyand7outof57forrespiratorysystemsubjectmattercategoriesinthe2014JournalCitationReports.The2014ImpactFactorwas5.282.
» Withthelargestattendanceever,theIASLC15thAnnualTargetedTherapiesintheTreatmentofLungCancerinSantaMonica,Calif.inFebruarygatheredtopscientiststodiscussthelatestadvancesinthetreatmentoflungcancerwithtargetedtherapies.
» TheyearalsosawasuccessfulEuropeanLungCancerConference(ELCC)inAprilandanannouncementfromIASLCandESMOthattheELCCwillbecomeanannualmeeting.
» IASLCalsoheldfocusedmeetingslikeoneonSmallCellLungCancerinNewYorkinApril2015andanEGFRmeetinginHuntingtonBeach,Calif.inAugust2015.
» ThePatientAdvocatesCommitteelaunchedseveralnewinitiativesincludingaPatientAdvocacyTrackatWCLC,uniqueregistrationratesforadvocates,survivorsandadvocacyorganizations,andcreationofpatientlocalliaisonsandadvocacytravelgrants.
42IASLC
Organizational GrowthGOAL 4 - IASLC is committed to long-term, global growth in membership.
» Meetinganaggressivegoalof5,000activemembersin2015,IASLCenrolledarecordofmorethan1,500newmembersbytheendoftheyear.
» WhilemembershiphistoricallyincreasesduringWCLCyears,IASLCimprovedthedatasharingandregistrationprocessthisyeartocapturemembershipasindividualscompletedWCLCregistration.Inaddition,manynewmemberstookadvantageofthemulti-yeardiscountofferattheWCLCinDenver.
» IASLCretainedandrecovered88percentofformermembersandlapsedmembers, whichisanincreaseoverpastyears’ retentionrates.
» IncreasedpromotionofthefreeFellowmembership,availabletoFellows,Residents,andTraineesinalldisciplines,ledtogrowthinthismembercategory.Weencourageallmembersto“Invite-a-Fellow”orutilizetheGroupFellowRegistrationtomakesureearlycareerphysiciansandinvestigatorscanbenefitfromthisincrediblevalue.
Professional Membership AssociationGOAL 5 - IASLC values the work of its volunteer members, who advance the IASLC mission through active participation and effective leadership.
» Asapilotprogram,IASLClaunchedaMembershipBoothpresenceatsocietiesforThoracicSurgery,PulmonologyandMedicalOncologyinEuropeandNorthAmerica,andwecontinuetoincreaseIASLCexposureinunder-representedspecialtiesandregionsoftheworld.
» IASLCestablishedagoalofeducatingtheentireteamofprovidersforlungcancerpatients,extendingtopathologists,diagnosticradiologists,nursesandalliedhealthprofessionals,communitypractitionersandindustryprofessionals.Tofurtherthatgoal,IASLCupdateditsmembercommunicationstoincludelanguagetomakeitclearthatIASLCmembershipisvaluabletoanyonewhoisinvolvedinlungcanceraroundtheworld.
» TheIASLCVirtualLibrarylaunchedin2015witheducationalcontentfromWCLC2015and2013availabletomembersontheIASLCwebsite.The8thEditionTNMStagingCardProposalscontinuedtobeoffered,freeofcharge,atmeetingsaroundtheworld.
43ANNUAL REPORT 2015
Charitable Giving and Philanthropic RelationshipsGOAL 6 - IASLC solicits philanthropic funds to support its research and educational programs.
» CentraltotheIASLCandtheIASLCFoundationisthemissiontosupporttheeducationoffellowsandyounginvestigators.Since2000,theIASLChasfundedmorethan80fellowships,11inthemostrecentyear.
» ThroughgenerousgiftstotheIASLCFoundation,wecanexpandourfellowshipprogram,creatingmoreprogramsliketheInternationalMentorshipProgram.
» In2015,theFoundationhadastrongstartwithdonationslargeandsmall.WelookforwardtoexpandingdonationstotheFoundationin2016aswereachouttomembersandcommunitypartners.
Operational SoundnessGOAL 7 - To accomplish its mission, the IASLC is committed to operational excellence and fiscal responsibility.
» TheIASLCends2015withabudgetsurplusfortheyearafterresponsiblymanagingthebudget(slowlygrowingtheassetbasewhileremainingfiscallyresponsible)andafterrunningafinanciallysuccessfulWorldConference(WCLC2015).
» NegotiatingacontractwithanewpublisherfortheJTOallowstheIASLCtoleveragenewopportunities,toprovideourmemberswithinformationinnewformats,andgivestheorganizationabetterrevenuesourcefrom theJournal.
» Expansionofthe“BestOf”seriesallowsthemostrelevantandinformativescientificdatatobeaccessedbymorepeopleworldwide.
» IASLChasplanstogrowtheofficebyseveralnewmembers(newspaceisleasedandinthedesignphaseandthreeofthenewstaffmembersbeganworkinJanuary2016)inordertotakeadvantageofnewopportunitiesinthisrapidlyprogressingfield,andalsotoprovideabettervarietyofservicesforourmembers.
44IASLC
IASLC FoundationTheIASLCFoundation’smissionistosupporttheeducationoffellowsandyounginvestigatorsdestinedtobecomethenextgenerationoflungcancerphysiciansandscientists.Since2000,theIASLChasfunded 80fellowships,11inthemostrecentyear.WiththehelpoftheIASLCFoundation,wecanexpandthisnumberinthefutureandassistmorepeopleincreatingnewandbetterwaystocombatlungcancer.
Todatemembershavedonatedover$250,000tohelpfundthesefellowships.Withourexpandedfundraisingefforts,theskyisthelimit.Ifyouwouldliketodonate tothisworthycause,pleasevisitourwebsite: iaslc.org/foundation.
In2015,theFoundationhadastrongstartwithagenerousdonationfromDr.AdiF.Gazdar.RelyingonthissubstantialgiftasseedmoneyallowstheIASLCFoundationtostartfundingour2016fellowships.However,thisisjustthestart.Weanticipate2016willseegreatstridesaswegrowourdonationbase.
We are grateful for the contribution made by those on this full list of 2015 donors:
$200,000 and aboveAdiF.Gazdar
$3,000 - $5,000CarolynM.DreslerDavidR.GandaraChristianManegold
$1,000 - $3,000AlexA.Adjei
BioBridgeStrategies (in honor of Denise Aberle, MD)
PaulA.Bunn,Jr.DavidPaulCarbone
QuincyChuBenCreelan
MartinEdelmanJeffreyA.EngelmanEdwardB.GaronPeterGoldstrawDavidH.HarpoleFredR.HirschJamesR.Jett
KarenKellyAaronMansfieldJohnD.MinnaRonNatale
GregoryA.OttersonRomanPerez-Soler
NaiyerRizviLeeRosen
DavidR.SpigelRolfStahel
MasahiroTsuboiVolderWacheck
GlenandLynneWeissJamesYang
$500 - $1,000PhilipD.BonomiMichaelJ.BoyerJulieBrahmer
JeffreyCrawfordJeremyJ.ErasmusLaurieE.Gaspar
LeoraHorn
MarkG.KrisChristineLovly
JoelNealSureshS.RamalingamKarenL.ReckampCharlesM.Rudin
NicoleRuizAlanB.Sandler
SumitraThongprasertPaulVanHoutteNiseYamaguchi
Under $500ChristianAdonizioShaymaaAhmedNewtonAlvesNaokoAragane
DavidBallJamesBartlett
LyudmiaBazhenovaSusanBlackwellAliceBraae
GiovanniLCarboni
Adi F. Gazdar
45ANNUAL REPORT 2015
LuisEduardoWerneckCarvalho
GuadalupeCedilloLeeChoon-TaekLjiljanaCilicEdwardConteJeffreyM.CraneJesusE.Davila
LarsB.DrivsholmWilfriedE.E.Eberhardt
TakashiEtoEtsuoFujita
MasahiroFukuokaAdamGamzon
ArunKumarGoelJhanelleGrayMarkR.GreenTomaszGrodzkiZhongpingGu
JamesU.GuachallaToshiyukiHarada
MasatoshiHasegawaKazushigeHayakawaNinaHelbekkmo
ThomasA.HensingFranciscoM.HeraldeIII
ShioriHikawaTeodorHorvathMichaelHumerKlausLIrion
HelgiJ.IsakssonDoloresIsla
MingLeeJangSureeratJaruhathaiTakeshiJohkoh
MichaelJonesRosalynJuergens
RyuKanzakiEdwardKimJooHangKimEbenezerKioJiroKitamuraKatsuyukiKiuraStephenC.LamCoreyJ.LangerYannLeCocguic
JayM.LeeJungShinLeeJangMingLeeNatashaLeighlRolfLewensohnTianhongLiHamadLia
KatsuakiMaeharaManuelMagallanesMitchellMageeJoAnnMoranMarceloMuinoSilviaNovelloYuichiroOheJiroOkami
MeinoshinOkumuraMariaC.PietanzaRobertPirkerIgorPolyakovZhouQingNealReady
KristinRicheimerGregoryRiely
BarbaraAnnRyan
LuciannoH.P.SantosArnoldM.Schwartz
DavidShamesKazuhikoShibataArthurTSkarinMatthewSteligaEmilyStone
ShigekiSugiyamaMinakoSumiKenjiSuzukiIrfanTastepeGuillermoJoséTemperley
MarkusTiemannMugeTor
ShinichiToyookaWilliamD.TravisMingS.Tsao
RosaireVaillancourtPaulVanSchil
GregoryM.M.VideticMaximilianvonLaffert
HeatherWakeleeWilliamWalsh
JohnWetheringtonDeborahA.WhippenStephenK.WilliamsonHiromasaYamamotoDavidF.Yankelevitz
MeiLingYapXuchaoZhangYongZhang
The legacy of
John Fisher
John Fisher became ill
in 2015 and rapidly
passed away from
mesothelioma, a thoracic
cancer. His wife, Lauren,
established a fund in
his memory, John’s
Legacy, honoring his
life’s focus on making
a difference in the lives
of others. Two-thirds
of the proceeds raised
by John’s Legacy will
go toward the IASLC
Foundation, specifically
to aid in efforts based out
of Colorado. DavidCarbone,Chair
FredR.Hirsch,CEOandSecretaryDavidGandara,TreasurerGiorgioScagliotti,Member
TonyMok,Member
IvarSamrén,MemberMarcBraunstein,Member
IASLC Foundation Board
46IASLC
TheIASLCcontinuestofocusonimplementingnewprogramsandinitiativesthathelpsupportourmembersandourmission.
Inthecomingyear,wewillgrowourmembershipandouractivities,sharingmoreknowledgeandbestpracticesaboutlungcancerthaneverbefore.In2016,theIASLCwillrenewourfocusonAsiawhilemaintainingourhighstandardsworldwide.Thisyearmarksthestartofanewage–itwillbethefirsttimetheWorldConferenceonLungCancerisheldannuallyandwelookforwardtoseeingallofourmembersinViennainDecember2016.
WhilewefocusontheimplementationoftheannualWCLC,ourcommitmentstoregionalactivitieswillcontinue.TheIASLCwillalsoexpandonregionalmeetingsinNorthAmericawithourChicagomeeting,inLatinAmericawiththeLatinAmericanLungCancerMeeting,(LALCA),inAsiawiththeAsianPacificLungCancerMeeting
(APLCC),andtogetherwithESMOinEurope,theEuropeanLungCancerMeeting(ELCC).
TheIASLCalsoacknowledgestheimportanceofhavingexpertsfocusingonspecifictopicsandprovidingguidanceforfuturedevelopmentsinspecificareas,andtherefore,wewillexpandourmeetingportfoliotoincludesmaller-focusedmeetings.Wewillalsofocusonprovidingguidancethroughscientificprojects,suchasthenewPD-L1Blueprint,andpublicationssuchastherevisedALK-ROS1Atlas.
Ourmembershipcontinuestoexpand,includingadvocates,patients,nursesandfieldrepresentatives.Wenowhavemembersinnearly100differentcountriesasmorepeopleinourfieldrecognizeIASLCasthegloballeaderinlungcancer.
TheIASLCFoundationgarnersmoresupportweeklyaswecontinuetouncoveroutreachopportunitiesparticularlyinsupportofmorefellowshipsandeducationalactivities.Inaddition,asdemandgrowsforthesupportfromtheIASLCstaff,wewillexpandboththenumberofourstaffandthesizeoftheheadquartersspace.
Inthecomingyear,wewillcontinuetoupdatetheIASLC/CAP/AMPguidelinesformoleculartestingforpersonalizedtherapy.TheIASLC,inconjunctionwithUICC,willpublishthenew(8thedition)stagingsystemforintrathoracictumorsbasedon
workbytheIASLCPathologyCommittee.ThecommitteewillalsowidelydistributethenewWHO Classification of Tumours of the Lung, Pleura, Thymus and Heart.
In2016,theIASLChopestoestablishaworldwidemoleculardatabasetoprovideinvestigatorswithopportunitiestocorrelatenumerousmolecularabnormalities,manyofwhicharerare,toclinical,demographicandtreatmentcharacteristics.Additionally,lookforthearrivalofotherIASLCprogramsthatwillaidincommunicationbetweenhealthprofessionalsandpatientsandexpandourreach.
TheIASLCwillalsocontinuetohostmeetingsacrosstheglobe,largeandsmall,beforeweculminatewiththeWCLCinDecember.Itisthroughtheseopportunitiestoshareknowledgewitheachotherthatwecan movethelineinthefightagainst lungcancer.
Weknowthatlungcancerscreeningcanreducelungcancermortalitysignificantlyandisrecommendedforthosedefinedashigh-risk.TheIASLCwillcontinuetoencouragemorescreeningaroundtheworld.Wearealsolookingtothefuturefornewandbetterwaystodetectthoracicmalignanciesearlier,aswellasfocusingontobaccocontrolandbetterpreventionmeasures,aswecontinueourmissiontoreducelungcancermortalityallovertheworld.
Future Perspective
47ANNUAL REPORT 2015
IASLC in PublicationsAstheonlyglobalmedicalsocietydedicatedtoconqueringthoracicmalignances,IASLC’sactivities,especiallytheWCLC,servedasthebasisformanypublicationsandresearchstudiesin2015.ThefollowinglistcontainscitationsofthosepublicationsaslistedinPubMed,forthecriteria“IASLC”or“InternationalAssociationfortheStudyofLungCancer.”IASLC’sreputationandrecognitioncontinuestogrowasmembersandnon-membersreferencetheorganizationintheirwork.
Aproteomicprofilingoflaser-microdissectedlungadenocarcinomacellsofearlylepidic-types.
KatoY,NakamuraH,TojoH,NomuraM,NagaoT,KawamuraT,KodamaT,OhiraT,IkedaN,FehnigerT,Marko-VargaG,NishimuraT,KatoH.
ClinTranslMed.2015Dec;4(1):64.doi:10.1186/s40169-015-0064-3.Epub2015Jul3.
AccuracyoftheIASLC/ATS/ERShistologicalsubtypingofstageIlungadenocarcinomaonintraoperativefrozensections.
TrejoBittarHE,IncharoenP,AlthouseAD,DacicS.
ModPathol.2015Aug;28(8):1058-63.doi:10.1038/modpathol.2015.71.Epub2015May29.
Associationbetweenhigh-resolutioncomputedtomographyfindingsandtheIASLC/ATS/ERSclassificationofsmalllungadenocarcinomasinJapanesepatients.
KudoY,MatsubayashiJ,SajiH,AkataS,ShimadaY,KatoY,KakihanaM,KajiwaraN,OhiraT,NagaoT,IkedaN.
LungCancer.2015Oct;90(1):47-54.doi:10.1016/j.lungcan.2015.07.007.Epub2015Jul26.
AssociationofIASLC/ATS/ERSHistologicSubtypesofLungAdenocarcinomaWithEpidermalGrowthFactorReceptorMutationsin320ResectedCases.
NakamuraH,SajiH,ShinmyoT,TagayaR,KurimotoN,KoizumiH,TakagiM.
ClinLungCancer.2015May;16(3):209-15.doi:10.1016/j.cllc.2014.10.004.Epub2014Oct25.
Changeofjunctionsbetweenstations10and4inthenewInternationalAssociationfortheStudyofLungCancerLymphNodeMap:avalidationstudyfromasingle,tertiaryreferralhospitalexperience.
LeeS,LeeHY,LeeKS,YieM,ZoJ,ShimYM,HanJ,AhnJH.
Chest.2015May;147(5):1299-306.doi:10.1378/chest.14-0717.
Clinicalevaluationofanewtumour-node-metastasisstagingsystemforthymicmalignanciesproposedbytheInternationalAssociationfortheStudyofLungCancerStagingandPrognosticFactorsCommitteeandtheInternationalThymicMalignancyInterestGroup.
FukuiT,FukumotoK,OkasakaT,KawaguchiK,NakamuraS,HakiriS,OzekiN,HirakawaA,TateyamaH,YokoiK.
EurJCardiothoracSurg.2015Nov7.doi:pii:ezv389.[Epubaheadofprint]
ClinicalimpactofthenewIASLC/ATS/ERSlungadenocarcinomaclassificationforchestsurgeons.
NakamuraH,TakagiM. SurgToday.2015Nov;45(11):1341-51.doi:10.1007/s00595-014-1089-8.Epub2014Nov23.
CloseassociationofIASLC/ATS/ERSlungadenocarcinomasubtypeswithglucose-uptakeinpositronemissiontomography.
NakamuraH,SajiH,ShinmyoT,TagayaR,KurimotoN,KoizumiH,TakagiM.
LungCancer.2015Jan;87(1):28-33.doi:10.1016/j.lungcan.2014.11.010.Epub2014Nov27.
Closerelationoflargecellcarcinomatoadenocarcinomabyhierarchicalclusteranalysis:implicationsforhistologictypingoflungcanceronbiopsies.
HammerSH,PrallF. ApplImmunohistochemMolMorphol.2015Sep;23(8):550-7.doi:10.1097/PAI.0000000000000121.
CorrelationbetweenMETproteinexpressionandMETgenecopynumberinaCaucasiancohortofnon-smallcelllungcancersaccordingtothenewIASLC/ATS/ERSclassification.
WeingertnerN,MeyerN,VoegeliAC,GuenotD,RenaudS,MassardG,FalcozPE,OllandA,MennecierB,GaubMP,LindnerV,GhnassiaJP,QuoixE,ChenardMP,Beau-FallerM.
Pathology.2015Jun;47(4):320-8.doi:10.1097/PAT.0000000000000269.
48IASLC
Correlationsbetweenpathologicsubtypes/immunohistochemicalimplicationandCTcharacteristicsoflungadenocarcinoma≤1cmwithground-glassopacity.
WuF,CaiZL,TianSP,JinX,JingR,YangYQ,LiYN,ZhaoSH.
ZhongguoYiXueKeXueYuanXueBao.2015Apr;37(2):163-70.doi:10.3881/j.issn.1000-503X.2015.02.006.
CytopathologyofpulmonaryadenocarcinomawithasinglehistologicalpatternusingtheproposedInternationalAssociationfortheStudyofLungCancer/AmericanThoracicSociety/EuropeanRespiratorySociety(IASLC/ATS/ERS)classification.
RodriguezEF,DacicS,PantanowitzL,KhalbussWE,MonacoSE.
CancerCytopathol.2015May;123(5):306-17.doi:10.1002/cncy.21532.Epub2015Mar18.
Developmentandvalidationofanomogramforpredictingsurvivalinpatientswithresectednon-small-celllungcancer.
LiangW,ZhangL,JiangG,WangQ,LiuL,LiuD,WangZ,ZhuZ,DengQ,XiongX,ShaoW,ShiX,HeJ.
JClinOncol.2015Mar10;33(8):861-9.doi:10.1200/JCO.2014.56.6661.Epub2015Jan26.
Diagnosticyieldofendobronchialultrasound-guidedtransbronchialneedleaspirationformediastinalstaginginlungcancer.
Fernández-BussyS,LabarcaG,CanalsS,CaviedesI,FolchE,MajidA.
JBrasPneumol.2015May-Jun;41(3):219-24.doi:10.1590/S1806-37132015000004466.English,Spanish.
EGFRanalysis:currentevidenceandfuturedirections.
BellevicineC,MalapelleU,deLucaC,IaccarinoA,TronconeG.
DiagnCytopathol.2014Nov;42(11):984-92.doi:10.1002/dc.23142.Epub2014Mar12.Review.
EGFRL858Rmutationisassociatedwithlungadenocarcinomapatientswithdominantground-glassopacity.
YangY,YangY,ZhouX,SongX,LiuM,HeW,WangH,WuC,FeiK,JiangG.
LungCancer.2015Mar;87(3):272-7.doi:10.1016/j.lungcan.2014.12.016.Epub2015Jan5.
EvaluationoftheproposedInternationalAssociationfortheStudyofLungCancer(IASLC)/InternationalThymicMalignanciesInterestGroup(ITMIG)stagingrevisionsinthymicwell-differentiatedneuroendocrinecarcinomapatients.
ZhaoY,ShiJ,FanL,YangJ,HuD,ZhaoH. EurJCardiothoracSurg.2015May1.doi:pii:ezv137.[Epubaheadofprint]
Follow-upofpatientsafterstereotacticradiationforlungcancer:aprimerforthenonradiationoncologist.
HuangK,PalmaDA;IASLCAdvancedRadiationTechnologyCommittee.
JThoracOncol.2015Mar;10(3):412-9.doi:10.1097/JTO.0000000000000435.
IdentifyingTargetedStrategiestoImproveSmokingCessationSupportforCancerPatients.
WarrenGW,DibajS,HutsonA,CummingsKM,DreslerC,MarshallJR.
JThoracOncol.2015Nov;10(11):1532-7.doi:10.1097/JTO.0000000000000659.
ImpactoftheInternationalAssociationfortheStudyofLungCancer/AmericanThoracicSociety/EuropeanRespiratorySocietyclassificationofstageIAadenocarcinomaofthelung:CorrelationbetweencomputedtomographyimagesandEGFRandKRASgenemutations.
WangT,ZhangT,HanX,LiuXI,ZhouN,LiuY. ExpTherMed.2015Jun;9(6):2095-2103.Epub2015Apr14.
InternationalAssociationfortheStudyofLungCancer/AmericanThoracicSociety/EuropeanRespiratorySocietyclassificationpredictsoccultlymphnodemetastasisinclinicallymediastinalnode-negativelungadenocarcinoma.
YehYC,KadotaK,NitadoriJI,SimaCS,RizkNP,JonesDR,TravisWD,AdusumilliPS.
EurJCardiothoracSurg.2015Sep15.doi:pii:ezv316.[Epubaheadofprint]
Lungadenocarcinoma:SustainedsubtypingwithimmunohistochemistryandEGFR,HER2andKRASmutationalstatus.
SousaV,RodriguesC,SilvaM,AlarcãoAM,CarvalhoL.
RevPortPneumol(2006).2015May-Jun;21(3):113-25.doi:10.1016/j.rppnen.2014.09.009.Epub2015Mar11.
Lungcancerandconcurrentorsequentiallymphoma:Twocasereportswithhypersensitivitytobevacizumabandareviewoftheliterature.
PezzutoA,PirainoA,MariottaS. OncolLett.2015Feb;9(2):604-608.Epub2014Nov20.
49ANNUAL REPORT 2015
Metastaticindexofnon-small-celllungcancerandlong-termsurvival.
PoullisM,ShackclothM,PageR,Asanti-SiawJ,WoolleyS,MedirattaN.
AsianCardiovascThoracAnn.2015Feb;23(2):185-90.doi:10.1177/0218492314545833.Epub2014Aug7.
MitosistrumpsTstageandproposedinternationalassociationforthestudyoflungcancer/americanthoracicsociety/europeanrespiratorysocietyclassificationforprognosticvalueinresectedstage1lungadenocarcinoma.
DuhigEE,DettrickA,GodboltDB,PauliJ,vanZwietenA,HansenAR,YangIA,FongKM,ClarkeBE,BowmanRV.
JThoracOncol.2015Apr;10(4):673-81.doi:10.1097/JTO.0000000000000446.
Mitoticarrestdeficient-like1iscorrelatedwithpoorprognosisinsmall-celllungcanceraftersurgicalresection.
LiD,MengQ,ZhangH,FengT,LiuM,CaiL. TumourBiol.2015Oct24.[Epubaheadofprint]
Molecularalterationsinnon-small-celllungcancer:perspectivefortargetedtherapyandspecimenmanagementforthebronchoscopist.
Czarnecka-KujawaK,YasufukuK. Respirology.2014Nov;19(8):1117-25.doi:10.1111/resp.12377.
Moleculartestingforselectionofpatientswithlungcancerforepidermalgrowthfactorreceptorandanaplasticlymphomakinasetyrosinekinaseinhibitors:americansocietyofclinicaloncologyendorsementofthecollegeofamericanpathologists/internationalassociationforthestudyoflungcancer/associationformolecularpathologyguideline.
RekhtmanN,LeighlNB,SomerfieldMR. JOncolPract.2015Mar;11(2):135-6.doi:10.1200/JOP.2014.002303.Epub2014Dec16.Noabstractavailable.
Multimodalitytherapyforlocallyadvancedthymomas:Apropensityscore-matchedcohortstudyfromtheEuropeanSocietyofThoracicSurgeonsDatabase.
LeuzziG,RoccoG,RuffiniE,SperdutiI,DetterbeckF,WederW,VenutaF,VanRaemdonckD,ThomasP,FaccioloF;ESTSThymicWorkingGroup.
JThoracCardiovascSurg.2015Aug15.doi:pii:S0022-5223(15)01481-6.10.1016/j.jtcvs.2015.08.034.[Epubaheadofprint]
MutationalProfileandNewIASLC/ATS/ERSClassificationProvideAdditionalPrognosticInformationaboutLungAdenocarcinoma:AStudyof125PatientsfromBrazil.
deMeloAC,KarendeSáV,SternbergC,OlivieriER,WerneckdaCunhaI,FabroAT,CarraroDM,deBarroseSilvaMJ,PimentaInadaHK,deMelloES,SoaresFA,TakagakiT,FerreiraCG,CapelozziVL.
Oncology.2015;89(3):175-86.doi:10.1159/000376552.Epub2015Apr1.
Nonpredominantlepidicpatterncorrelateswithbetteroutcomeininvasivelungadenocarcinoma.
MäkinenJM,LaitakariK,JohnsonS,MäkitaroR,BloiguR,Lappi-BlancoE,KaarteenahoR.
LungCancer.2015Oct17.doi:pii:S0169-5002(15)30083-0.10.1016/j.lungcan.2015.10.014.[Epubaheadofprint]
Nuclearestrogenreceptor-αexpressionisanindependentpredictorofrecurrenceinmalepatientswithpT1aN0lungadenocarcinomas,andcorrelateswithregulatoryT-cellinfiltration.
KadotaK,EguchiT,Villena-VargasJ,WooKM,SimaCS,JonesDR,TravisWD,AdusumilliPS.
Oncotarget.2015Sep29;6(29):27505-18.doi:10.18632/oncotarget.4752.
OutsourcingcytologicalsamplestoareferrallaboratoryforEGFRtestinginnon-smallcelllungcancer:doestheorymeetpractice?
VigliarE,MalapelleU,BellevicineC,deLucaC,TronconeG.
Cytopathology.2015Oct;26(5):312-7.doi:10.1111/cyt.12221.Epub2014Nov7.
PeripherallungadenocarcinomaswithKRASmutationsaremorelikelytoinvadevisceralpleura.
RapariaK,VillaC,RajR,CaglePT. ArchPatholLabMed.2015Feb;139(2):189-93.doi:10.5858/arpa.2013-0759-OA.Epub2014Apr2.
Perspectivesofnovelimagingtechniquesforstaging,therapyresponseassessment,andmonitoringofsurveillanceinlungcancer:summaryoftheDresden2013PostWCLC-IASLCState-of-the-ArtImagingWorkshop.
HenzlerT,GoldstrawP,WenzF,PirkerR,WederW,ApfaltrerP,MeyerM,BuesingK,CrinoL,FennellD,FinkC,GrunenwaldD,ManegoldC,PilzL,SchoenbergSO,SureshS,VansteenkisteJ,VoigtW,WänglerB,Schmid-BindertG.
JThoracOncol.2015Feb;10(2):237-49.doi:10.1097/JTO.0000000000000412.
50IASLC
Predictingtheprognosisoflungcancer:theevolutionoftumor,nodeandmetastasisinthemolecularage-challengesandopportunities.
Rami-PortaR,AsamuraH,GoldstrawP. TranslLungCancerRes.2015Aug;4(4):415-23.doi:10.3978/j.issn.2218-6751.2015.07.11.
Prognosticimpactandclinicopathologicalcorrelationsofthecribriformpatterninpulmonaryadenocarcinoma.
WarthA,MuleyT,KossakowskiC,StenzingerA,SchirmacherP,DienemannH,WeichertW.
JThoracOncol.2015Apr;10(4):638-44.doi:10.1097/JTO.0000000000000490.
Prognosticimpactofpattern-basedgradingsystembythenewIASLC/ATS/ERSclassificationinAsianpatientswithstageIlungadenocarcinoma.
ZhaoZR,XiSY,LiW,SituDR,ChenKM,YangH,SuXD,LinYB,LongH.
LungCancer.2015Nov4.doi:pii:S0169-5002(15)30095-7.10.1016/j.lungcan.2015.10.026.[Epubaheadofprint]
PrognosticvalueoftheIASLC/ATS/ERSclassificationandIMP3expressioninlungadenocarcinomaofChinesecases.
SunX,WeiP,ShenC,YangY,WangY,LiY,DuX.
AmJCancerRes.2015;5(7):2266-76.
PrognosticvalueofthenewIASLC/ATS/ERSclassificationofclinicalstageIAlungadenocarcinoma.
MurakamiS,ItoH,TsubokawaN,MimaeT,SasadaS,YoshiyaT,MiyataY,YokoseT,OkadaM,NakayamaH.
LungCancer.2015Nov;90(2):199-204.doi:10.1016/j.lungcan.2015.06.022.Epub2015Jul2.
PrognosticvalueofthenewInternationalAssociationfortheStudyofLungCancer/AmericanThoracicSociety/EuropeanRespiratorySocietyclassificationinstageIBlungadenocarcinoma.
XuCH,WangW,WeiY,HuHD,ZouJ,YanJ,YuLK,YangRS,WangY.
EurJSurgOncol.2015Oct;41(10):1430-6.doi:10.1016/j.ejso.2015.06.004.Epub2015Jun23.
ProgrammedDeath-Ligand1ImmunohistochemistryinLungCancer:Inwhatstateisthisart?
KerrKM,TsaoMS,NicholsonAG,YatabeY,WistubaII,HirschFR;IASLCPathologyCommittee.
JThoracOncol.2015Jul;10(7):985-9.doi:10.1097/JTO.0000000000000526.
RadiologicEvaluationofSmallLepidicAdenocarcinomastoGuideDecisionMakinginSurgicalResection.
WilshireCL,LouieBE,ManningKA,HortonMP,CastiglioniM,GordenJA,AyeRW,FarivarAS,VallièresE.
AnnThoracSurg.2015Sep;100(3):979-88.doi:10.1016/j.athoracsur.2015.04.030.Epub2015Jul29.
RadiologicPredictorsforClinicalStageIALungAdenocarcinomawithGroundGlassComponents:AMulti-CenterStudyofLong-TermOutcomes.
LiZ,YeB,BaoM,XuB,ChenQ,LiuS,HanY,PengM,LinZ,LiJ,ZhuW,LinQ,XiongL.
PLoSOne.2015;10(9):e0136616.doi:10.1371/journal.pone.0136616.
Relationshipbetweenhistopathologiccharacteristicsandepidermalgrowthfactorreceptormutationinlungadenocarcinoma.
WangK,GongH,LiX,YangZ,CaoP,WandC,JiangY,WangH,WangY,ZhangG.
ZhonghuaBingLiXueZaZhi.2015Mar;44(3):170-4.Chinese.
Reproducibilityof3histologicclassificationsand3stagingsystemsforthymicepithelialneoplasmsanditseffectonprognosis.
RodenAC,YiES,JenkinsSM,EdwardsKK,DonovanJL,LewisJE,CassiviSD,MarksRS,GarcesYI,AubryMC.
AmJSurgPathol.2015Apr;39(4):427-41.doi:10.1097/PAS.0000000000000391.
RoleofCTandPETImaginginPredictingTumorRecurrenceandSurvivalinPatientswithLungAdenocarcinoma:AComparisonwiththeInternationalAssociationfortheStudyofLungCancer/AmericanThoracicSociety/EuropeanRespiratorySocietyClassificationofLungAdenocarcinoma.
LeeHY,LeeSW,LeeKS,JeongJY,ChoiJY,KwonOJ,SongSH,KimEY,KimJ,ShimYM.
JThoracOncol.2015Oct15.[Epubaheadofprint]
SolidcomponentandtumorsizecorrelatewithprognosisofstageIBlungadenocarcinoma.
XuS,XiJ,JiangW,LuS,WangQ. AnnThoracSurg.2015Mar;99(3):961-7.doi:10.1016/j.athoracsur.2014.10.079.Epub2015Jan27.
SolidPredominantHistologicSubtypeinResectedStageILungAdenocarcinomaIsanIndependentPredictorofEarly,Extrathoracic,MultisiteRecurrenceandofPoorPostrecurrenceSurvival.
UjiieH,KadotaK,ChaftJE,BuitragoD,SimaCS,LeeMC,HuangJ,TravisWD,RizkNP,RudinCM,JonesDR,AdusumilliPS.
JClinOncol.2015Sep10;33(26):2877-84.doi:10.1200/JCO.2015.60.9818.Epub2015Aug10.
51ANNUAL REPORT 2015
Stereotacticablativeradiotherapyforcentrallylocatedearlystagenon-small-celllungcancer:whatwehavelearned.
ChangJY,BezjakA,MornexF;IASLCAdvancedRadiationTechnologyCommittee.
JThoracOncol.2015Apr;10(4):577-85.doi:10.1097/JTO.0000000000000453.
Subsolidpulmonarynodules:CT-pathologiccorrelationusingthe2011IASLC/ATS/ERSclassification.
LiaoJH,AminVB,KadochMA,BeasleyMB,JacobiAH.
ClinImaging.2015May-Jun;39(3):344-51.doi:10.1016/j.clinimag.2014.12.009.Epub2014Dec20.Review.
SubtypeClassificationofLungAdenocarcinomaPredictsBenefitFromAdjuvantChemotherapyinPatientsUndergoingCompleteResection.
TsaoMS,MarguetS,LeTeuffG,LantuejoulS,ShepherdFA,SeymourL,KratzkeR,GrazianoSL,PopperHH,RosellR,DouillardJY,Le-ChevalierT,PignonJP,SoriaJC,BrambillaEM.
JClinOncol.2015Oct20;33(30):3439-46.doi:10.1200/JCO.2014.58.8335.Epub2015Apr27.
Theanaplasticlymphomakinasetestingconundrum.
CondeE,TaniereP,Lopez-RiosF. ExpertRevMolDiagn.2015Feb;15(2):161-3.doi:10.1586/14737159.2015.997713.Epub2015Jan12.
TheclinicalutilityofMemorialSymptomAssessment-ShortFormandCondensedMemorialSymptomAssessmentScaleinTurkishlungcancerpatients.
YüceegeM,SanisoğluB,FıratH,ErsoyY,SevgiE,KurtEB.
ClinRespirJ.2015Apr;9(2):221-7.doi:10.1111/crj.12127.Epub2014Mar20.
TheIASLCLungCancerStagingProject:ProposalsfortheRevisionoftheMDescriptorsintheForthcomingEighthEditionoftheTNMClassificationofLungCancer.
EberhardtWE,MitchellA,CrowleyJ,KondoH,KimYT,TurrisiA3rd,GoldstrawP,Rami-PortaR;InternationalAssociationfortheStudyofLungCancerStagingandPrognosticFactorsCommittee,AdvisoryBoardMembers,andParticipatingInstitutions.
JThoracOncol.2015Nov;10(11):1515-22.doi:10.1097/JTO.0000000000000673.
TheIASLCLungCancerStagingProject:ProposalsfortheRevisionsoftheTDescriptorsintheForthcomingEighthEditionoftheTNMClassificationforLungCancer.
Rami-PortaR,BolejackV,CrowleyJ,BallD,KimJ,LyonsG,RiceT,SuzukiK,ThomasCFJr,TravisWD,WuYL;IASLCStagingandPrognosticFactorsCommittee,AdvisoryBoardsandParticipatingInstitutions.
JThoracOncol.2015Jul;10(7):990-1003.doi:10.1097/JTO.0000000000000559.
TheInternationalAssociationfortheStudyofLungCancerLymphNodeMap:ARadiologicAtlasandReview.
KimJH,vanBeekEJ,MurchisonJT,MarinA,MirsadraeeS.
TubercRespirDis(Seoul).2015Jul;78(3):180-9.doi:10.4046/trd.2015.78.3.180.Epub2015Jun30.Review.
TheInternationalThymicMalignancyInterestGroupthymicinitiative:astate-of-the-artstudyofthymicmalignancies.
DetterbeckF,KorstR. SeminThoracCardiovascSurg.2014Winter;26(4):317-22.doi:10.1053/j.semtcvs.2015.02.002.Epub2015Feb7.
TreatmentofPeripheralNon-SmallCellLungCarcinomawithStereotacticBodyRadiationTherapy.
RoachMC,VideticGM,BradleyJD;IASLCAdvancedRadiationTechnologyCommittee.
JThoracOncol.2015Sep;10(9):1261-7.doi:10.1097/JTO.0000000000000610.
TumoralCD10expressioncorrelateswithhigh-gradehistologyandincreasesriskofrecurrenceinpatientswithstageIlungadenocarcinoma.
KadotaK,BuitragoD,LeeMC,Villena-VargasJ,SimaCS,JonesDR,TravisWD,AdusumilliPS.
LungCancer.2015Sep;89(3):329-36.doi:10.1016/j.lungcan.2015.06.003.Epub2015Jun15.
UsingfrozensectiontoidentifyhistologicalpatternsinstageIlungadenocarcinomaof≤3cm:accuracyandinterobserveragreement.
YehYC,NitadoriJ,KadotaK,YoshizawaA,RekhtmanN,MoreiraAL,SimaCS,RuschVW,AdusumilliPS,TravisWD.
Histopathology.2015Jun;66(7):922-38.doi:10.1111/his.12468.Epub2015Feb5.
UtilizationoftheInternationalAssociationfortheStudyofLungCancerandWang’snodalmapfortheidentificationofmediastinumandhilarlymphnodes.
XiaY,MaY,AriasS,LeeH,WangKP. ThoracCancer.2015Jul;6(4):464-8.doi:10.1111/1759-7714.12206.Epub2015Jan8.
Video-assistedthoracoscopicsurgerylobectomyforlungcancerisassociatedwithalower30-daymorbiditycomparedwithlobectomybythoracotomy.
LaursenLØ,PetersenRH,HansenHJ,JensenTK,RavnJ,KongeL.
EurJCardiothoracSurg.2015Jun18.doi:pii:ezv205.[Epubaheadofprint]
52IASLC
13100 East Colfax Avenue, Unit 10 | Auora, Colorado, USA 80011 | www.iaslc.org